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HNF4α Hepatocyte nuclear factor 4 α 
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LCA Lithocholic acid 
NRF1 Nuclear respiratory factor 1 
PB Phenobarbital 
PBG Porphobilinogen 
PEPCK Phosphoenolpyruvate carboxykinase 
PGC-1α Peroxisome proliferator activated receptor γ coactivator α 
PPAR Peroxisome proliferator activated receptor 
PXR Pregnane X receptor 
RXR 9-cis Retinoic acid receptor 
SHP Short heterodimer partner 
siRNA Small interfering RNA 
UDCA Ursodeoxycholic acid 
Abstract 
ALAS1 is the rate limiting enzyme of heme synthesis. It is highly inducible in liver in 
cases of increased heme demand, such as drug metabolism or in inducible hepatic 
porphyrias. The clinical hallmark of these rare genetic disorders of enzymes of heme 
synthesis are neuropsychiatric attacks precipitated by drugs, hormones and fasting. 
The xenosensing nuclear hormone receptors CAR and PXR have been previously 
shown to mediate ALAS1 induction by classical inducer drugs (Podvinec et al. PNAS, 
2004). The molecular details of the action of other precipitating factors, however, have 
not been elucidated so far. Studying the molecular mechanism of the fasting response 
as well as the involvement of additional nuclear hormone receptors in the 
transcriptional regulation of ALAS1 was the aim of this study. 
We show that ALAS1 is regulated by the peroxisome proliferator-activated receptor γ-
coactivator α (PGC-1α) via an insulin sensitive FOXO1 site within the promoter of 
ALAS1. In vivo studies confirm that ALAS1 is induced at the transcriptional level upon 
fasting. This effect is lost in liver specific PGC-1α knock-out animals, clearly 
demonstrating that PGC-1α is the master regulator of the fasting response. 
Interestingly, induction of ALAS1 by classical inducer phenobarbital is preserved, 
indicating that PGC-1α is not essential for the drug mediated induction of the gene.  
In an attempt to identify additional factors regulating ALAS1, we have analyzed by 
phylogenetic footprinting the genomic sequence of human ALAS1. At minus 14kb of the 
transcriptional start site a novel response element for the bile acid receptor FXR, a 
nuclear receptor involved in lipid and glucose homeostasis as well as detoxification, 
was identified. Based on the molecular characterization of the FXR response element, 
and functional data in primary human hepatocytes and in mice as well as on genomic 
sequence analysis, we demonstrate that the response of ALAS1 to bile acid is unique 
to primates. 
In addition, multiple enhancer modules identified by cross species sequence 
comparison were shown to be activated by hepatocyte nuclear factor 4α (HNF4α). 
Chromatin immunoprecipitation confirmed the binding of this factor in a native 
chromatin context. We therefore hypothesize that the liver enriched transcription factor 
HNF4α is required for basal expression and liver specific induction of ALAS1.  
In conclusion, in the present work we describe and discuss a complex regulatory 
network consisting of FOXO1, the nuclear receptors CAR, PXR, FXR and HNF4α as 
well as the coactivator PGC-1α, which mediate the transcriptional regulation of ALAS1 
to various stimuli, such as fasting, or to the exposure to endo- and xenobiotics. 
 
 1 Introduction 
1.1 Heme synthesis 
Heme is a pivotal molecule for life, and its synthesis takes place in every cell of the 
body except the mature erythrocyte. Hemeproteins are involved in a numerous crucial 
biologic functions such as oxygen binding (hemoglobin, myoglobin), oxygen 
metabolism (oxidases, peroxidases and catalases) and electron transfer (respiratory 
cytochromes) (Atamna, 2004). Moreover heme plays an important role by providing 
carbon monoxide (CO) through its catabolism, a signaling molecule whose wide 
biological function only started to be disclosed (Kim et al., 2006). Recent findings also 
revealed that heme may function as a circadian modulator of various cellular processes 
(Kaasik and Lee, 2004). To avoid heme accumulation and cellular toxicity heme levels 
need to be tightly controlled; this is achieved by a fine balance between heme 
biosynthesis and its catabolism by the enzyme heme oxygenase.  
 
Figure 1   Heme synthesis pathway involves eight enzymatic steps. ALA, 5-aminolevulinic acid; 
ALAD, ALA dehydratase; PBG, porphobilinogen; PBGD, PBG deaminase; HMB, 
hydroxymethylbilane; Uro-P, uroporphyrinogen; Copro-P, coproporphyrinogen; Cpo, 
coproporphyrinogen oxidase; Proto-P, protoporphyrinogen 
The heme synthesis pathway is schematically represented in Fig. 1. It consists of 8 
enzymatic steps, partly located in the mitochondria, partly in the cytoplasm. The 
pathway starts at the mitochondrial matrix with the condensation of glycine and succinyl 
CoA to δ-aminolevulinic acid (ALA), a step, driven by the enzyme δ-aminolevulinic acid 
synthase (ALAS).  ALA is subsequently transported to the cytoplasm, where 2 
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molecules of ALA are used to form the pyrolle ring of porphobilinogen (PBG). 4 PBGs 
are finally converted to protoporphyrin IX through decarboxylation and oxidation steps, 
which begin in the cytosol and end in the mitochondria. Ferrochelatase catalyzes the 
last step of the synthesis by incorporating iron into protoporphyrin-IX generating Fe-
protoporphyrin IX, or alternatively called heme b. 
There are 3 functional forms of heme known in eukaryotes: heme a, b and c, which 
slightly differ in substituents of the porphyrin ring system and the way they are 
incorporated into apoproteins. Heme b is the most abundant form and, like heme a, is 
bound through coordination to the iron ion to amino acid side chains of the proteins. 
Heme b is found in cytochromes P450, hemoglobin, myoglobin and respiratory 
complexes II and III. In contrast heme c is covalently bound through the two vinly side 
chains to the protein itself, such as in cytochrome c and nitric oxid synthetase. 
Formation of heme a requires two major modification: farnesylation and addition of a 
formyl group to position 8 of the Fe-protoporphyrin-IX. Mitochondrial complex IV is the 
only protein in the cell that contains heme-a. Ageing and neurodegenerative diseases 
such as Alzheimer disease have been connected to deficiency of heme-a and 
subsequent reduction in complex IV (Atamna, 2004) highlighting the pivotal role of 
heme in the maintenance of crucial cellular processes.  
Thunnell compared the heme synthesis pathway with a pipeline having components of 
variable diameter according to the enzymes capacities (Thunell, 2000). The bottleneck 
and therefore rate limiting step of heme synthesis is its first step driven by ALAS. There 
are two isoforms of this enzyme encoded by different genes on separate 
chromosomes, erythrocyte specific ALAS2, expressed in erythroid cells only, and the 
ubiquitously expressed ALAS1. The two isoformes are completely differently regulated 
according to the need of the different tissues. In erythroid progenitor cells, where the 
bulk of body’s heme is synthesized, heme is constantly demanded for the incorporation 
into globin chains to form hemoglobin. The acquisition of iron is the rate limiting step 
stimulating ALAS2 transcription via an iron response element in the promoter .  
The liver is the organ where the second highest amount of heme is synthesized. The 
majority of it is incorporated into cytochromes P450, microsomal monooxygenases 
responsible for steroid hormone and bile acid synthesis and for detoxification of 
endogenous and exogenous substances. 
In contrast to the bone marrow, where cell differentiation and cell division regulate the 
expression of heme synthesis enzymes, heme synthesis in liver must be flexible to 
adapt to the ever changing metabolic demand of the hepatocyte. Therefore ALAS1 is 
highly inducible by a variety of stimuli and simultaneously under the control of a 
negative feedback exerted by the end-product heme. Together with a free heme 
induced catabolism these mechanism ensure a fine tuning of cellular hepatic heme 
levels according to the current metabolic need.  
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1.2 Hereditary Defects of Heme Synthesis: The Porphyrias 
The porphyrias are clinically very heterogeneous diseases resulting from defects in one 
of the enzymes of the heme synthesis pathway. Partial defects for all the enzymes of 
the heme synthesis pathway except ALAS1 are known. Depending on the location of 
the enzymatic defect within the pathway, different patterns of accumulation of 
intermediates and accordingly different clinical symptoms are observed. The location of 
the different enzymatic defects and corresponding porphyrias are given in Fig. 2.  
 
 
 
Figure 2   Hereditary enzyme deficiencies of heme synthesis pathway leading to ‘Porphyrias’ 
Partial defect of all of the enzmyes (except ALAS1) are known and the diseases are 
referred to as porphyrias. Clinically they are classified in acute, inducible porphyrias 
(bold) and/or skin porphyrias (light). Adapted from Thunell et al. 2000. 
Photosensitivity due to accumulation of porphyrins in skin is the main clinical 
manifestation of the so called acute or chronic skin porphyrias. In contrast inducible, 
acute hepatic porphyrias are characterized by intermittent attacks of neuropsychiatric 
dysfunction always accompanied by increased porphyrin precursors ALA and PBG 
(Kauppinen, 2005, Anderson et al., 2005). 
There are four different forms of acute porphyrias. Acute intermittent porphyria (AIP), 
variegata porphyria (VP) , hereditary coproporphyrinuria (HC) and the extremely rare 
ALAD deficiency (ALAD-P). The attacks of these hepatic porphyrias are 
indistinguishable from each other but all show increased urinary excretion of porpyhrin 
precursors. The acute attack is a potentially fatal condition characterized by severe 
abdominal pain, autonomic dysfunction and a motor neuropathy that may progress to 
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paralysis. Clinical manifestation are present in only a subset of gene carriers and arise 
after puberty and are more frequent in women (Kauppinen, 2005). The acute attacks 
may be precipitated by a number of known triggering factors, such as drugs, which 
induce cytochromes P450, fasting, hormones and any form of stress but most often 
remain unexplained. Acute attacks are treated by withdrawal of the causative agent, 
high carbohydrate load and most efficiently by intravenous administration of hemin. If 
dehydration and imbalance of electrolytes ensue, attacks can be life threatening and 
require intensive care. It is still under debate if increased ALA concentration in the 
nervous system or a neuronal heme deficiency account for symptoms in acute attacks 
(Sengupta et al., 2005) (Meyer et al., 1998). Liver transplantation has been reported to 
be successful in long term treatment of severe recurrent episodes. In a recent report, 
porphyrin precursors in the patients urine returned to normal already 24h after 
transplantation, and remained so for a follow-up of one and a half year (Soonawalla et 
al., 2004). These data clearly demonstrate, that the liver is the major source of excess 
porphyrin precursor production.  
In order to understand the molecular basis of this liver specific and excessive 
overproduction of porpyhrin precursors, the regulation of ALAS1 has to be studied.  
1.3 ALAS1 and its regulation 
An important aspect of ALAS1 regulation in liver is the strong negative feedback, which 
is exerted by the end product heme. Heme represses its own synthesis via three 
different mechanism. It inhibits import of cytosolic ALAS1 precursor protein into the 
mitochondrial matrix, directly inhibits ALAS1 transcription (Kolluri et al., 2005) and 
reduces its mRNA stability (Thunell, 2000, May et al., 1995). After exposure of cells to 
heme, ALAS1 mRNA half-life decreases from 130 minutes to 40 minutes, illustrating 
the highly efficient repression (May et al., 1995). However, the exact mechanisms are 
still not understood and subject of ongoing research (Roberts et al., 2005). In the past it 
has been assumed that depletion of this so-called regulatory heme pool indirectly 
increases ALAS1 activity upon heme consuming stimuli. However, studies of our 
laboratory and others shed light into several aspects of transcriptional regulation of 
ALAS1, which demonstrate a direct stimulatory effects on ALAS1. What is known so far 
about the transcriptional regulation of  ALAS1 will be briefly summarized below.  
The ALAS1 promoter contains a consensus TATA box and two nuclear respiratory 
factor 1 (NRF1) sites, important for basal expression as demonstrated by site directed 
mutagenesis (Braidotti et al., 1993). 5’RACE of mRNA isolated from different tissues in 
rat revealed that up to six different transcription start sites exist, some of them 
independent of the TATA box (Roberts and Elder, 2001). The authors conclude that 
depending on the tissue, different start sites are used, which may account for the tissue 
specific expression and regulation of the enzyme. In liver, transcription is initiated 
almost exclusively via the TATA box.  
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The phenomenon of a repressive effect of glucose and insulin on ALAS1 has been 
known for long (Giger and Meyer, 1981). Canepa and coworkers described two 
different cyclic AMP response elements binding CREB in the ALAS1 rat promoter 
responding to protein kinase A (PKA) activation (Giono et al., 2001) in cell based 
transactivation assays. In addition they demonstrated that hepatocyte nuclear factor 3 
beta (HNF3beta), a factor negatively regulated by insulin, was binding to two adjacent 
sites within the promoter (Scassa et al., 2004). However, mutation of the two HNF3beta 
sites did not completely abolish the repressive effect of insulin on ALAS1, indicating, 
that additional factors are involved in the transcriptional repression by insulin.  
More than 80% of the heme synthesized in liver is used for incorporation into 
cytochromes P450 necessary for the metabolism of endogenous and exogenous 
substances. Hence the highest demand for heme is clearly exerted by the 
administration of drugs. The mechanisms how drugs directly upregulate heme 
synthesis has been deciphered only recently by different members of our group. Drug 
response elements binding the xenosensing nuclear receptors chicken X receptor 
(CXR), constitutive androstane receptor (CAR) and pregnane X receptor (PXR) in the 
far upstream region of ALAS1 have been characterized in three different species: 
chicken, mouse and human (Fraser et al., 2002, Fraser et al., 2003, Podvinec et al., 
2004). Together these data demonstrate that the principle action of nuclear receptors 
with respect to the drug response of ALAS1 is conserved over evolution.  
 
1.4 The Nuclear Hormone Receptor Family of Transcription 
Factors 
Nuclear hormone receptors are ligand activated transcription factors that work in 
concert with coactivators and corepressors to regulate gene expression. Nuclear 
receptor proteins have a characteristic modular structure, consisting of (from the N-
terminus to C-terminus) a modulatory A/B domain, a highly conserved DNA binding 
domain containing two zinc fingers (DBD), a flexible hinge region and a ligand binding 
domain (LBD) responsible for dimerization and ligand dependent transactivation 
(Mangelsdorf et al., 1995). Nuclear receptors bind either as homodimers or as 
heterodimers to characteristic DNA response elements, consisting of a hexameric 
consensus halfsite AGGTCA arranged as direct (DR), inverted (IR) or everted repeats 
(ER). Full activation of nuclear receptors is achieved upon binding of ligands, such as 
hormones, fatty acids, bile acids, oxysterols or a variety of xenobiotics. Nuclear 
receptors thus exert diverse crucial roles in metabolic homeostasis, development, 
inflammation and detoxification (Francis et al., 2003).  
Nuclear hormone receptors constitute one of the largest groups of transcription factors 
in animals. In mammals the superfamily of nuclear receptors is composed of 
approximately 50 different functional genes, with 48 in humans, 47 in rats and 49 in 
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mice (Zhang et al., 2004c). The current official nomenclature divides the superfamily 
into 6 subfamilies (NR0-6) based on their phylogenetic tree (NUCLEAR RECEPTORS 
NOMENCLATURE COMMITTEE, 1999). Most prominent members of the nuclear 
receptors, to mention only a few, are the steroid hormone receptors, such as estrogen 
receptor (ER), androgen receptor (AR) and the mineralocorticoid receptor (MR) and 
glucocortiocid receptor (GR). The nuclear receptors controlling fat, glucose, cholesterol, 
and bile acid metabolism include the peroxisome proliferator-activated receptors 
(PPARs), liver X receptors (LXRs) and farnesoid X receptor (FXR). 
Several nuclear receptors are involved in detoxification processes. They include 
members of the NR1 subfamily, such as CAR, PXR, vitamin D receptor (VDR) and 
farnesoid X receptor (FXR) as well as one member of the NR2 family, hepatocyte 
nuclear factor 4α HNF4α. The ones addressed in this study will be briefly introduced 
below.   
1.4.1 The xenosensing nuclear receptors PXR and CAR 
The pregnane X receptor (PXR) and constitutive androstane receptor (CAR) belong to 
the NR1H subfamily and are the classical xenosensing nuclear hormone receptors 
activated by array of structurally diverse ligands (Handschin and Meyer, 2003). PXR 
has a broader substrate specificity than CAR and PXR ligands include commonly used 
drugs, such as rifampicin, natural and synthetic steroids as well as plant products. Only 
a few direct CAR ligands are known, e.g. Citco and TCPOBOP for human and mouse 
CAR respectively. Other CAR activators, such as phenobarbital (PB) or bilirubin, do not 
directly bind to the receptor, but induce its translocation to the nucleus by a mechanism 
which involves phosphorylation and/or dephosphorylation events (Kawamoto et al., 
1999) (Hosseinpour et al., 2006). However the detailed mechanism is not fully 
understood so far. Together with their obligate heterodimerization partner retinoic X 
receptor RXR, CAR as well as PXR bind to DR3, DR4 or ER6 type of response 
elements. Members of the cytochrome P450 family are their prototypical target genes, 
such as human CYP3A4 for PXR and CYP2B6 for CAR. Other target genes include 
sulfotransferases, glucuronosyltransferases and transport proteins such as multidrug 
resistant protein 3 (MRP3) all involved in detoxification processes (reviewed in (Tirona 
and Kim, 2005)).  
1.4.2 The bile acid activated receptor Farneosid X receptor - FXR 
Soon after the nuclear hormone receptor FXR (NR1H4) was cloned, it was found to be 
activated by farnesols, intermediates of the cholesterol synthesis pathway, hence its 
name (Forman et al., 1995). Later primary and secondary bile acids as well as their 
gluco- and tauroconjugates were shown to effectively activate FXR, among them 
configures the primary bile acid chenodeoxycholic acid as the most potent natural 
ligand (Wang et al., 1999). FXR also heterodimerizes with RXR and binds mostly to 
inverted repeats spaced by 1 nucleotide (IR1) in the flanking region of its target genes. 
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In response to ligand binding, FXR regulates a variety of genes involved in bile acid, 
cholesterol, triglyceride and lipoprotein metabolism (for a recent review and a 
comprehensive list of target genes see (Kalaany and Mangelsdorf, 2006).  
Targeted disruption of the FXR gene in mice confirmed its critical role in bile acid and 
lipoprotein metabolism. FXR knock-out mice exhibit elevated plasma cholesterol and 
triglycerides levels and excessive accumulation of fat in the liver (Sinal et al., 2000). 
More recently several reports highlight an effect of FXR activation on glucose 
homeostasis. Its final role however, remains controversial (Claudel et al., 2005). 
Interestingly, FXR, CAR and PXR share a common set of target genes, namely 
cytochrome P450 CYP3A4 (Gnerre et al., 2004), UDP-glucuronosyltransferases 
(Barbier et al., 2003), sulfotransferases (Song et al., 2001), or the transport proteins, 
such as MRP2 (Kast et al., 2002), all involved in the elimination and excretion of 
potentially toxic bile acids as well as xenobiotics.  
Of note, researchers recently have identified four isoforms of the murine and human 
FXR (FXRα1, α2, α3, and α4) due to alternative promoter usage and alternative splicing 
(Huber et al., 2002, Zhang et al., 2003). The four isoforms differ by their N terminus and 
by the existence of a four-amino acid insertion in the hinge region. Interestingly, FXR 
isoforms lacking the four amino acid insertion (α2 and α4) bind FXR response elements 
(FXREs) with higher affinity and display stronger transactivation of the promoters of 
some FXR target genes, i.e. ileal bile acid binding protein (IBABP), but not others, i.e. 
short heterodimer partner (SHP). However the precise differences of the four isoforms 
with respect to various FXR signaling pathways is not yet fully understood. 
1.4.3 Hepatocyte Nuclear Factor 4 – HNF4α 
HNF4α is a nuclear hormone receptor (NR2A1) highly conserved from men to insects. 
HNF4α belongs to the liver enriched transcription factors and is considered to be the 
major regulator of the hepatocyte phenotype (Watt et al., 2003). In mammals it is 
expressed at highest level in liver, kidney, intestine and pancreas (Sladek et al., 1990). 
HNF4α null mice die during early embryogenesis due to a failure in endoderm 
development (Chen et al., 1994). Liver specific knock-out animals have been 
generated, which show a severely disturbed lipid homeostasis at the onset of 5 weeks 
of age and an increased mortality of >70% by 8 weeks of age (Hayhurst et al., 2001). 
These reports demonstrate the pivotal role of HNF4α in early development as well as 
for the maintenance of proper adult liver function.  
A large number of HNF4α target genes have been identified, which are involved in key 
metabolic pathway such as cholesterol, fatty acid and glucose homeostasis as well as 
xenobiotic metabolism (for an overview: www.sladeklab.ucr.edu/info.html). HNF4α 
binds DNA exclusively as a homodimer, mostly to direct repeats spaced by one 
nucleotide (DR1) elements in the promoters of its target genes. The essential fatty acid 
linoleic acid has been found by affinity purification and subsequent gas chromatography 
and mass spectrometry analysis to be bound to the HNF4α ligand binding pocket in 
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mammalian cells (Sladek; EMBO 2005). Functional data, demonstrating increased 
transcriptional activity upon linoleic acid treatment or increased coactivator recruitment 
are lacking to date. It is debated, if linoleic acid indeed serves as a classical nuclear 
hormone receptor ligand. Therefore, HNF4α is still regarded as orphan receptor. In 
contrast, a number of coactivators have been shown to potently increase HNF4α 
transcriptional activity in a ligand independent manner, including GRIP1, SRC1 and 
PGC-1α (Rhee et al., 2003, Wang et al., 1998).  
Mutation in and near the human HNF4α gene are associated with an autosomal 
dominant form of diabetes, MODY1 (Yamagata et al., 1996), and with the common form 
of type 2 diabetes respectively (Silander et al., 2004), further underlining the role of 
HNF4α in glucose homeostasis.   
The HNF4α gene gives rise to several isoforms, via internal splicing and transcription 
from two alternative promoters. HNF4α1 and HNF4α7 are the prototypic isoforms 
derived from the two promoters and differ with respect to their tissue distribution as well 
as coactivator recruitment. In liver HNF4α1 is by far the most predominant isoform, 
while HNF4α7 dominates in pancreas (Briancon et al., 2004). An interesting recent 
paper highlights the central role of HNF4α1 isoform in the regulation of CAR, 
underlining the link between these nuclear hormone receptors (Briancon and Weiss, 
2006).  
 
1.4.4  The versatile coactivator PGC-1α 
In 1998, PGC-1α was identified as a PPARγ interacting protein in brown adipose tissue 
(Puigserver et al., 1998). Since then a variety of transcription factors from inside and 
outside the family of nuclear hormone receptors were shown to interact with PGC-1α. 
These experiments document that PGC-1α is a versatile coactivator and affects various 
aspects of cellular energy status and oxidative metabolism. Its expression is high in all 
tissues rich in mitochondria, such as brown adipose tissue, heart and skeletal muscle. 
Through the interaction mainly with nuclear respiratory factor 1 and 2 (NRF1 and 
NRF2) PGC-1α plays a central role in mitochondrial biogenesis (Scarpulla, 2002).  
In normal ‘fed’ liver, expression of PGC-1α is low, however in the fasted state, PGC-1α 
is robustly increased. PGC-1α is able to activate near all aspects of the hepatic fasting 
response, including gluconeogenesis, fatty acid β oxidation and ketogenesis (Herzig et 
al., 2001, Rhee et al., 2003, Yoon et al., 2001). It does so by activating key hepatic 
transcription factors, such as HNF4α, PPARα, GR, and the forkhead transcription factor 
FOXO1 (Puigserver et al., 2003). The above described nuclear hormone receptors 
FXR, CAR and PXR have been added to the list of transcription factors co-activated by 
PGC-1α (Bhalla et al., 2004, Shiraki et al., 2003, Zhang et al., 2004b). 
Together with PGC1β and PGC related coactivator (PRC) PGC-1α builds up the family 
of PGC1 coactivators. The three members show high homology in their structure: a N- 
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terminal activation domain, a central regulatory domain and a C-terminal RNA binding 
domain. Three LXXLL domains are responsible for the interaction with different nuclear 
hormone receptors. Not much is known about the function of PRC so far. PGC-1β 
shows a similar tissue distribution to PGC-1α and a number of transcription factors 
known to interact with PGC1α were also shown to be co-activated by PGC-1β. In liver 
PGC-1β also is highly induced in fasted state, but while having only a minimal effect of 
gluconeogenic genes, this factor potently enhances the expression of genes involved in 
fatty acid oxidation and ketogenesis (Lin et al., 2003). In addition PGC-1β, and not 
alpha, plays a central role in hepatic lipogenesis and cholesterol synthesis in response 
to high a fat diet (Lin et al., 2005b). Table 1 gives an overview of transcription factors 
known to interact with PGC-1α and -1β. 
 
Table 1 Transcription factors known to interact with PGC1 coactivators; adapted from Lin et 
al. 2005 
Transcription 
factor PGC-1α PGC-1β  Function References 
NRF-1 + + mitochondrial genes (Wu et al., 1999) 
NRF-2 + ND mitochondrial genes (Mootha et al., 2003) 
ERR?,?,? + + mitochondrial genes (Schreiber et al., 2003, Mootha et al., 2004) 
PPAR ?,?,? + +/- fatty-acid oxidation (Wang et al., 2003, Puigserver et al., 1998) 
LXR?,? + + lipoprotein secretion (Lin et al., 2005b) 
ER?,? + + ? (Kressler et al., 2002) 
GR + - gluconeogenesis (Yoon et al., 2001, Kressler et al., 2002) 
FXR + ND triglyceride metabolism (Zhang et al., 2004b) 
PXR + ND unknown (Bhalla et al., 2004) 
CAR + ND fasting response, unknown (Shiraki et al., 2003) 
FOXO1 + - gluconeogenesis (Puigserver et al., 2003) 
HNF4? + + gluconeogenesis (Yoon et al., 2001)  (Lin et al., 2002) 
SREBP1a, 1c, 2 ?  + lipogenesis/ lipoprotein secretion (Lin et al., 2005b) 
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1.5 Comparative Genomics as a Novel Tool to Identify 
Regulatory Elements 
In the past it was predicted that most of the DNA within the human genome does not 
have a function and that most if not all function is contained within protein coding 
regions. Initial comparison of human and rodent genomes (Waterston et al., 2002) 
(Gibbs et al., 2004) indicate that about 5% or more of the bases within the genome are 
under purifying selection. However, protein coding genes are believed to account for 
only about 1.5% of the human genome, which may leave around 3.5% of the bases in 
the genome that are thought to be functional, but not to code for proteins. This 
conserved non-coding sequence has been the subject of intense interest. It is now 
believed that it consists of structural elements, non-coding RNAs and of regulatory 
elements involved in gene expression (Dermitzakis et al., 2005).  
 
If the assumption holds true that regulatory regions are conserved in evolution, they 
could be identified by cross species sequence comparison. In the last years several 
alignments programs, based on global alignment, such as AVID (Bray et al., 2003) and 
LAGAN (Brudno et al., 2003), or local alignment algorithms, such as BLASTZ 
(Schwartz et al., 2003), were created to specifically align long genomic sequences. One 
of the first reports that successfully applied this approach for the identification of 
regulatory regions was from Loots et al. who characterized a longe-range regulator of 
interleukin 4, 13, and 5 (Loots et al., 2000) within 1 megabase of sequences analyzed. 
Now it is generally well established that non-coding conserved regions can represent 
functional regulatory elements (Frazer et al., 2004b). And the method of so-called 
phylogenetic footprinting, which filters long genomic sequences for segments 
conserved across species, has become an attractive approach to reduce the number of 
false-positive predictions reported by conventional search algorithms for transcription 
factor binding sites (Lenhard et al., 2003). 
 
 2 Aim of the Studies 
 
A number of factors can provoke attacks of hepatic porphyria. Among those, drugs 
have been shown to directly upregulate ALAS1 transcription via the nuclear hormone 
receptors CAR and PXR. We hypothesized that other triggering factors, such as fasting 
and endogenous ligands of nuclear receptors also induce ALAS1 directly at the 
transcriptional level. The goal of this thesis was to elucidate the transcriptional network 
regulating ALAS1 in order to get insight into the pathogenesis of acute porphyric crises.  
 
During these studies we addressed the following questions: 
 
 
1) What are the molecular mediators of the fasting response of ALAS1? In 
particular, does PGC-1α, known to mediate the adaptive response to fasting in 
the liver, have an effect on hepatic heme synthesis? 
 
 
2) Can we identify new regulatory regions of ALAS1 by using a comparative 
genomic approach?  
 
 
 
3) Do additional nuclear hormone receptors involved in detoxification, such as 
FXR, regulate ALAS1? 
 
 
4) ALAS1 is expressed ubiquitously, however only in liver ALAS1 is inducible at 
the transcriptional level. What determines this liver specific inducibility of 
ALAS1? Does the master regulator of hepatic gene expression, HNF4α, play a 
role in basal as well as drug induced expression of ALAS1? 
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3.1 Abstract 
δ-amino levulinic acid synthase 1 (ALAS1) is the rate limiting enzyme of heme 
synthesis in liver and is highly regulated to adapt to the metabolic demand of the 
hepatocytes. In the present study we describe that human hepatic ALAS1 is a new 
direct target of the bile acid activated nuclear receptor farnesoid X receptor (FXR). Our 
experiments in cultures of primary human hepatocytes reveal that ALAS1 transcripts 
and activity is increased upon stimulation by the most potent natural ligand of FXR, 
chenodeoxycholic acid (CDCA). Treatment of human liver slices with CDCA resulted in 
a similar increase in ALAS1 expression. The synthetic FXR agonist GW4064 was able 
to induce ALAS1 expression as well as activity in cultures of primary human 
hepatocytes. Moreover, by overexpression of a constitutively active form of FXR, the 
response of ALAS1 mRNA to GW4064 was significantly increased. In agreement with 
this, we identified and characterized a FXR response element in the 5’-flanking region 
of human ALAS1. The region was able to trigger a 5 fold increase in luciferase activity 
upon CDCA treatment. Site directed mutagenesis demonstrated the functionality of the 
IR1 element, and binding of FXR/RXR heterodimers was evidenced in gel shift 
experiments. Together these data strongly support a role of bile acid activated FXR in 
the regulation of ALAS1 and consequently of hepatic heme and porphyrin synthesis. In 
addition, our findings suggest that endogenous bile acids may precipitate 
neuropsychiatric attacks in patients with acute hepatic porphyrias.  
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3.2 Introduction 
Synthesis of heme is indispensable for life and takes place in every cell of the body 
except mature erythrocytes. The bulk of heme is synthesized in bone marrow for the 
production of hemoglobin and in liver, where it is incorporated into various heme 
proteins, such as cytochromes P450, catalases, peroxidases and respiratory 
cytochromes. The pathway of heme synthesis consists of 8 enzymatic steps and is 
initiated by the condensation of glycine and succinyl CoA to δ-aminolevulinic acid 
(ALA), a reaction catalyzed by the enzyme δ-aminolevulinic acid synthase (ALAS). 
There are two isoforms of this enzyme encoded by different genes on separate 
chromosomes, erythrocyte specific ALAS2, expressed in erythroid cells only, and the 
ubiquitously expressed ALAS1 (Thunell, 2000).  
Since either excess or deficiency of heme is detrimental to the cell, heme synthesis 
needs to be tightly controlled. In non-erythroid cells the rate of synthesis is controlled at 
its first step. Accordingly, ALAS1 is highly regulated in different cellular contexts to 
ensure adequate levels of intracellular heme. A negative feedback is exerted by a 
regulatory heme pool by several mechanisms including i) inhibition of the transfer of 
ALAS1 precursor protein into the mitochondrial matrix, ii) reduction of ALAS1mRNA 
stability and iii) direct inhibition of ALAS1 transcription (Thunell, 2000, May et al., 1995, 
Roberts et al., 2005) (Kolluri et al., 2005).  
Hereditary defects of heme synthesis lead to rare metabolic diseases referred to as 
porphyrias (Anderson et al., 2005, Kauppinen, 2005). Partial defects of all enzymes of 
the synthesis pathway except ALAS1 are known. Depending on the location of the 
enzymatic defect within the pathway, different patterns of accumulation and excretion 
of intermediates and accordingly different clinical symptoms are observed. 
Photosensitivity due to accumulation of porphyrins in skin is the main clinical 
manifestation of some porphyrias. Inducible, acute hepatic porphyrias are 
characterized by intermittent attacks of neuropsychiatric dysfunction precipiated by a 
number of well-known stimuli, such as drugs, alcohol, sex steroids or fasting. These 
attacks are always associated with increased hepatic ALAS1 activity reflected by 
increased levels of the porphyrin precursors ALA and PBG in plasma and urine. Acute 
attacks are treated by withdrawal of the causative agent, high carbohydrate load and 
most efficiently by intravenous administration of hemin. If dehydration and imbalance of 
electrolytes ensue, attacks can be life threatening and require intensive care.  
It is still under debate if increased ALA concentration in the nervous system or a 
neuronal heme deficiency account for symptoms in acute attacks (Sengupta et al., 
2005, Soonawalla et al., 2004) (Meyer et al., 1998). However, progress has been made 
in understanding the molecular mechanisms of ALAS1 regulation in the liver. In the last 
years, members of the nuclear hormone receptor family of transcription factors, the 
xenosenors constitutive androstane receptor (CAR) and pregnane X receptor (PXR), 
were identified to mediate induction of ALAS1 by inducer drugs. We characterized drug 
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response elements in the far upstream 5’-flanking region of chicken, mouse and human 
ALAS1, demonstrating direct transcriptional upregulation of ALAS1 by these 
precipitating agents (Fraser et al., 2002, Fraser et al., 2003, Podvinec et al., 2004). 
Recently peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α), a 
coactivator involved in mitochondrial biogenesis and energy homeostasis, was shown 
to be the master regulator of the fasting response of ALAS1 by acting via an insulin 
sensitive FOXO1 site in the promoter (Handschin et al., 2005).  
 
For many years bile acids were mostly known as important products of cholesterol 
metabolism, acting as detergents necessary for the intestinal absorption of nutrients.  
More recently new biological functions of bile acids as signaling molecules in particular 
in lipid and glucose homeostasis have been discovered (for a recent review (Claudel et 
al., 2005)). Bile acid signaling in the liver is mostly mediated via the farnesoid X 
receptor (FXR), a member of the nuclear receptor family of ligand activated 
transcription factors. The most potent natural ligand of FXR is the primary bile acid 
chenodeoxycholic acid (CDCA). In addition lithocholic acid (LCA), deoxycholic acid 
(DCA), as well as their taurine and glycine conjugates, have been shown to directly 
bind to FXR (Makishima et al., 1999, Parks et al., 1999). FXR heterodimerizes with the 
retinoic X receptor RXR and binds to consensus sequences, most commonly an IR1 
(inverted hexameric nucleotide repeat separated by one nucleotide) in the flanking 
region of its target genes. FXR plays a critical role in bile acid homeostasis. Short 
heterodimer partner (SHP) is a one of the most studied direct targets of FXR and 
represses de novo synthesis via downregulation of CYP7A1 and CYP8B1, the two rate 
limiting enzymes in bile acid synthesis (Goodwin et al., 2000). Simultaneously FXR 
enhances the metabolism and excretion of bile acids. The enzymes induced by FXR, 
namely cytochrome P450 CYP3A4 (Gnerre et al., 2004), UDP-
glucuronosyltransferases (Barbier et al., 2003), sulfotransferases (Song et al., 2001), or 
the transport proteins, such as MRP2 (Kast et al., 2002), also are induced by drugs via 
CAR and PXR, two transcription factors critical for the elimination of xenobiotics in the 
liver (Handschin and Meyer, 2003). Thus the liver evolved redundant pathways in the 
detoxification of endogenous and exogenous compounds (Guo et al., 2003). Low or 
near physiological concentrations of primary bile acids induce drug metabolizing 
enzymes and transport proteins via FXR, whereas toxic concentration of bile acids in 
particular the secondary bile acid LCA and exogenous compounds activate CAR and 
PXR and thereby their target genes (Staudinger et al., 2001, Xie et al., 2000). 
 
One crucial enzyme for detoxification and therefore coregulated with cytochromes 
P450 via CAR and PXR is ALAS1, ensuring enough heme for newly synthesized 
apocytochromes. Since bile acids induce heme proteins such as cytochromes P450, 
we hypothesized that they also must affect heme synthesis.  
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Several lines of evidence indeed suggest a connection between bile acid homeostasis 
and the regulation of hepatic heme synthesis. The bile acid precursors 5β-cholestan-
3α,7α-diol and 5β-cholestan-3α,7α,12α-triol were shown in the past to induce ALAS1 
activity in chicken embryo hepatocytes (Javitt et al., 1973). In hepatobiliary diseases 
accompanied by cholestasis increased urinary excretion of porphyrins is a common 
feature. It has already been suggested that increased porphyrin synthesis contributes 
to this phenomenon (Gibson et al., 2000) (Rocchi et al., 2005) 
 
In the present study, we investigated the effect of bile acids on the rate-limiting enzyme 
of heme synthesis, ALAS1, in two human liver culture systems, primary culture of 
human hepatocytes and human liver slices. We identified the bile acid activated nuclear 
receptor FXR as a novel regulator of ALAS1 thereby connecting bile acid signaling and 
hepatic heme synthesis. 
  
3.3 Materials and Methods 
Chemicals 
All chemicals were purchased from Sigma (Buchs, Switzerland) unless stated 
otherwise. GW4064 was kindly provided by Dr T. M. Willson (GlaxoSmithKline, 
Research Triangle Park, North Carolina, USA). Mammalian expression plasmid for 
human FXR was previously described (Gnerre et al., 2004), pcDNA3 human PGC-1α 
was a kind gift from Dr. A. Kralli (The Scripps Research Institute, La Jolla, California, 
USA).  
Animal experiments 
C57/Bl6 wild-type animals were from a colony maintained at the Biozentrum as 
described (Gnerre et al., 2004). Animals were maintained on standard laboratory chow 
and were allowed food and water ad libitum. Ten to 16-week-old female mice (n = 4-5) 
were injected i.p. with vehicle alone (corn oil with 5% DMSO) or GW4064 40 mg/kg. 
After 16 h, animals were killed, liver tissue samples solubilized in 1 ml TRIzol TM 
reagent (Invitrogen) and total RNA was extracted. For the cholic acid feeding 
experiment, female animals (n=5) were either on standard laboratory chow or fed a 1% 
cholic acid diet for 1 week. Animals were killed, liver tissue samples solubilized in 1 ml 
TRIzol TM reagent (Invitrogen) and total RNA was extracted. 
Isolation and culture of primary human hepatocytes  
Liver tissue wedges (50-200mg) were obtained from consented patients undergoing 
surgical resections in the clinic of visceral surgery (Berne, Switzerland). Tissue was 
perfused via two cannulea with buffers heated to 37°C at a rate of 100 ml/min. Firstly 
PBS containing 10mM HEPES for 5 minutes followed by 500 ml of PBS HEPES 
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containing 2mM EGTA and the 500ml of the initial buffer to remove EGTA. The enzyme 
solution (0.05% collagenase, 0.02% dispase, 0.017% hyaluronidase and 0.02% 
DNase, in HBSS containing 5mM CaCl2) was then recirculated through the liver wedge 
for a period of 7-12 minutes until it was sufficiently softened. The tissue was 
mechanically disrupted in DMEM containing 10% fetal calf serum, filtered through 50-
micron sterile gauze and washed twice in DMEM and kept on ice in suspension. 
Hepatocytes were subsequently seeded on rat-tail collagen coated plastic dishes 
(25µg/cm2, BD Biosciences, Basel, Switzerland) at a density of 300’000 cells per well 
in 12-well plates in Dulbecco’s Minimum Essential Medium (Gibco BRL, Basel, 
Switzerland) supplemented with 10% heat inactivated fetal bovine serum (Gibco BRL), 
1µM dexamethasone (Sigma, Buchs, Switzerland), 50U/ml penicillin and 50µg/ml 
streptomycin (both from Gibco BRL). After overnight culture, the medium was replaced 
with serum free Williams’E medium (Invitrogen, Basel, Switzerland) supplemented with 
100nM hydrocortisone, 0.5x ITS (Insulin, Transferrin, Selenium; Sigma), 50U/ml 
penicillin and 50µg/ml streptomycin. Cells were kept for 24h under these conditions 
unless stated otherwise and subsequently exposed to chemicals as indicated in the 
figure legends. 
Preparation and culture of human liver slices 
Human liver slices were prepared as previously described (Elferink et al., 2004) and 
cultured individually in 6-well plates in 3.2 ml William’s medium E (Gibco, Auckland, 
NZ) supplemented with D-glucose (25 mM) and 50 µg/ml gentamicin, under continuous 
shaking at 37°C in a humidified atmosphere saturated with 5% carbogen. Slices were 
transferred to fresh medium and incubated in the presence or absence of 10 or 100 µM 
CDCA for 8, 16 and 24 hours. At the end of the incubation time, slices were frozen in 
liquid nitrogen and stored at -80C° until RNA was prepared. 
Isolation and culture of primary mouse hepatocytes 
For the preparation of mouse hepatocytes animals were anaesthetized with 
Ketamine/Xylazine (Sigma, Buchs, Switzerland). The hepatic portal vein was canulated 
and perfused with HEPES-EGTA (pH 7.4) at a flow rate of 8ml/min for 5 minutes. The 
liver was then perfused with collagenase (type 2, Worthington, Lakewood NJ, USA) for 
6 minutes. The perfusion solutions were continuously gassed with carbogen. The livers 
were excised into a Petri dish filled with Leibowitz’ L-15 medium (Sigma, Buchs, 
Switzerland) supplemented with 10% newborn calf serum (Invitrogen, Basel, 
Switzerland). Cells were filtered through a nylon mesh and centrifuged at 50xg at 4°C 
for 5 minutes three times. After determination of viability, cells were plated at a density 
of 400’000 cells/well (12 well plate) and were allowed to attach for 2 hours in William’s 
E medium without phenol red (Invitrogen, Basel, Switzerland), 10 % FCS, 4µg/ml 
insulin, 200µM glutamine and and 1% penicillin/streptomycin (50 IU/ml) on collagen-
coated dishes. Medium was replaced with serum free Williams’E medium as described 
for human hepatocytes and exposed to chemicals 24h later as indicated in the figure 
legends. 
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RNA isolation, reverse transcription and real-time PCR 
Total RNA was isolated with the Trizol TM reagent (Invitrogen). 1.2 µg total RNA from 
primary cells or 1 µg of mouse liver total RNA were reverse transcribed with the 
Moloney murine leukaemia virus reverse transcriptase (Promega, Catalys AG, 
Wallisellen, Switzerland) using either random hexamers p(dN)6 (Roche Diagnostics, 
Rotkreuz, Switzerland) or oligo-(dT)15 N primers (Promega), respectively. PCR was 
performed with the qPCR TM Mastermix Plus (Eurogentec GmbH, Köln, Germany). 
Primers and probes were optimized as indicated in Table 1. Transcript levels were 
quantified with an ABI Prism 7700 sequence detection system (PE Applied Biosystems, 
Boston, Massachusetts, USA) according to the manufacturer’s protocol. Briefly, relative 
transcript levels in induced cells or livers and untreated controls were determined using 
the relative quantification method measuring ΔΔCt (comparative threshold cycle 
method). The levels of either 18S or cyclophilin and GAPDH were used for the 
normalization of the human and mouse genes, respectively. 
Transfection of Primary Human Hepatocytes 
After overnight plating, cells were transfected with plasmid DNA using Effectene 
transfection reagent (Qiagen, Hombrechtikon, Switzerland) following the manufacturers 
recommendations. Transfection mixes contained 1µg of plasmid DNA (prepared using 
Endo Free® Plasmid Maxi Kit, Qiagen), 8µl Enhancer Buffer and 10µl Effectene per 
well to be transfected. 36h later cells were exposed to reagents for 10h followed by 
lysis and RNA preparation. 
ALAS activity assay 
ALAS activity was assayed as described (Sinclair et al., 1999) with the following 
modifications. Primary human hepatocytes were plated as described above except that 
600’000 cells per well in 6-well plates were used. After culturing in serum free 
conditions for 12h, cells were induced overnight with either vehicle (0.15% DMSO), 
250µM 4,6 dioxoheptanoic acid alone or together with 50µM CDCA, 1µM GW4064 or 
500µM phenobarbital. Induction medium was replaced by 700µl prewarmed glycine 
buffer (35mM Tris-HCl, pH 7.4, 30mM Na2HPO4, 8.5mM Na citrate 2H20, 8mM MgCl2, 
0.2mM pyridoxalphosphate, 10µM dioxoheptanoic acid, 5mM EDTA and 50mM glycine) 
and plates were incubated for additional 2h at 37°C. The assay was stopped by 
trichloracetic acid (5% final) and supernatant was taken for subsequent analysis of ALA 
production according to (Sinclair et al., 1999). Cells were lysed in standard lysis buffer 
for protein determination using the Bradford method. Data are given as nmol ALA 
produced per mg protein per hour.  
In silico analysis of human ALAS1 flanking region  
For cross-species sequence comparison a total of 66.7kb genomic sequence ranging 
from the 5’- to the 3’-neighboring annotated gene of human ALAS1 was used and 
included 43.7kb 5’-flanking, 16.3kb genic and 6.9kb 3’-flanking sequence. Multispecies 
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(human, chimpanzee mouse, rat and dog) sequence alignments produced by MULTIZ 
(Blanchette et al., 2004), which are based on pairwise sequence alignments performed 
by BLASTZ with subsequent chaining and netting, were retrieved from the Santacruz 
genome browser (genome.ucsc.edu). A total of 16 conserved blocks of non-coding 
sequences located from -27kb to + 19kb from the transcriptional start site as reported 
by MULTIZ were then individually scanned for putative IR1 elements using NubiScan 
algorithm with the provided FXR specific matrix based on 38 known binding sites from 
the literature and a score threshold of >0.62 (www.nubiscan.unibas.ch). The MULTIZ 
alignment shown in Fig. 8 includes sequences of human, chimpanzee, rhesus, rabbit, 
mouse, rat, dog and cow assemblies and was retrieved from genome.ucsc.edu.  
Plasmid Construction 
Fragments of human ALAS1 flanking region were PCR amplified using the previously 
isolated PAC clone harboring ALAS1 gene as template (Podvinec et al., 2004) and 
Pwo DNA Polymerase (Roche Diagnostics, Rotkreuz, Switzerland). Primers were 
designed using Primer 3 software (primer3_www.cgi v 02) with the following 
parameters: 24nt in length, 50% GC content, Tm 60°C, and restrictions sites added as 
indicated in Table 1. The fragments were cloned into pGL3 tk luciferase vector using 
standard cloning procedures. The 1.3kb promoter was cloned into pGL3 basic. 
Subfragments of the 795bp long -14kb ALAS1 construct were generated by restriction 
digest with AatII and PvuII (New England Biolabs, Bioconcept, Allschwill, Switzerland). 
The 175bp derived mutated construct was generated by PCR using complementary 
oligonucelotides mutated in the IR1 site (see Table 1) and Pfu Turbo DNA Polymerase 
(Stratagene, La Jolla, CA, USA). The products were digested with DpnI (New England 
Biolabs) to remove the parental DNA template and selected for constructs containing 
mutations. Plasmid DNA was prepared using the Qiagen sytem. All constructs were 
verified by sequencing.  
Transactivation assay 
Transactivation assays were carried out in CV-1 (monkey kidney) cells as previously 
described (Gnerre et al., 2004) with minor modifications. Briefly, cells were expanded 
for 3 days in DMEM-F12 without phenol red (Gibco BRL) and supplemented with 10% 
charcoal treated FBS. Subsequently, cells were plated onto 96- well dishes at a density 
of 25 000 cells per well and grown overnight. Cells were transiently transfected in 
OptiMemI (Invitrogen) using 1µl of LipofectAMINE reagent (Invitrogen) per well. 
Transfection mixes contained 8 ng receptor expression vector, 20ng coactivator 
expression vector, 20ng reporter vector and 60ng pRSV-βGal to a total of 108ng DNA 
per well. After 24h, cells were exposed to drugs or vehicle in DMEM-F12 supplemented 
with 10% charcoal stripped delipidated FBS (Sigma). 24h later, cell extracts were 
prepared using 200µl of passive lysis buffer (Promega) and 10µl of the supernatants 
were assayed for luciferase activities using the luciferase assay kit (Promega) and a 
Wallac 1420 Multilabel Counter. β-galactosidase activities were measured as 
previously described (Podvinec et al., 2004). Luciferase levels were normalized against 
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β-galactosidase values to compensate for variation in transfection efficiency. Data are 
presented as mean +/- standard deviation. All transfections were repeated at least two 
to four times in triplicates or quadruplicates. Statistical significance is defined in two-
tailed students t-test as p < 0.05 or p < 0.01 as indicated in the figures. 
Electromobility shift assay 
Human FXR and human RXRα were synthesized using the TNT T7 –coupled 
reticulocytes system (Promega). Double-stranded oligonucleotide probes were 
obtained by hybridizing single-stranded complementary oligonucleotides (Operon, 
Köln). Dimers with the sense sequences shown in Table I were labeled with [γ-32P] 
ATP using T4 polynucleotide kinase (NEB) and cleaned of unincorporated nucleotide 
using Sephadex Nick columns (Amersham, GE Healthcare, Otelfingen, Switzerland). 
3µl of in vitro translated nuclear receptors were incubated on ice for 30min with 2-5 
fmol of γ-32P-end-labeled dimerized oligonucleotide and 1µg of poly(dI)poly(dC) in 10 
mM HEPES-KOH, pH 7.9, 10% glycerol, 50mM KCl, 1mM MgCl2, 0.25mM 
dithiothreitol, and 0.25 mM phenylmethylsulfonyl fluoride. For competition assays, a 25-
200-fold excess of unlabeled dimerized oligonucleotides was added. For supershift 
experiments, 1µl of antibody against FXR (Santa Cruz Biotec. sc-13063 X) or 0.5 µl of 
monoclonal anti-mouse-RXR rabbit antibody (kindly provided by P. Chambon, Institut 
de Génétique et de Biologie Moléculaire et Cellulaire, Université Louis Pasteur, Illkirch, 
France) was added to the reaction mix. Reactions were analyzed by electrophoresis 
through 5% polyacrylamide gels in 0.25× Tris-borate EDTA buffer at 120V for 2 h. 
3.4 Results 
Bile acids induce ALAS1 mRNA in cultured primary human hepatocytes 
To study whether hepatic heme synthesis is regulated by bile acids, cultures of primary 
human hepatocytes were exposed to the primary bile acid CDCA, and analyzed for the 
expression levels of ALAS1. After 8h incubation of the cells in the presence of 50µM 
CDCA, ALAS1 transcripts increased 4.5-fold, an increase similar to the effect of the 
classical ALAS1 inducer phenobarbital (PB) at 500µM (Fig. 1A). Combination of PB 
and CDCA resulted in an additive effect as compared to single treatment. 
We then examined if other bile acids also were able to increase ALAS1 transcripts. 
Therefore cultured primary human hepatocytes were challenged with a set of different 
bile acids and again analyzed for the expression levels of ALAS1. In order the check for 
an intact bile acid signaling cascade, mRNA levels of SHP, a known bile acid 
responsive gene, were measured. As illustrated in Fig. 1B, the primary bile acids 
CDCA, cholic acid (CA) and ursodeoxycholic acid (UDCA; all at 50µM) and the 
secondary bile acid LCA (25µM) increased SHP as well as ALAS1 mRNA levels to 
various degrees. We conclude that endogenous substrates such as bile acids are able 
to increase ALAS1 to the same degree as inducer drugs.  
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Bile acids increase ALAS1 expression in human liver slices  
To test if our findings in primary culture are reproduced in a system where the tissue 
architecture of the liver is intact, we examined the effect of bile acids on gene 
expression in precision cut human liver slices. Human liver slices are a well established 
ex vivo model for human physiology (Elferink et al., 2004). Slices of three different 
donors were incubated for time intervals of 8, 16 and 24hrs at the low or physiological 
concentration of 10µM and at the toxic concentration of 100µM CDCA. Again SHP 
expression was measured as a positive control and found to be increased in all 3 
donors at both concentrations tested (data not shown). As depicted in Fig. 2, all three 
donors also showed an increase in ALAS1 mRNA expression upon CDCA treatment. 
The degree of induction and the time course of the response expectedly differed from 
one individual to another. Maximal induction was seen after 16h (donor A) or 24h 
(donor B and C). An increase in ALAS1 transcripts could be observed already at 10µM 
CDCA (donor A and B, 16 and 24h and donor C, 24h) suggesting physiological 
relevance of our findings.  
 
The FXR agonist GW4064 and overexpression of constitutively active FXR 
increase ALAS1 mRNA 
Since bile acids in addition to their potential to activate FXR may also affect alternative 
pathways, including activation of PXR, a known regulator of ALAS1, we used the 
synthetic agonist of FXR, GW4064, to test the specificity of the response. Primary 
human hepatocytes were cultured with increasing concentrations of GW4064. Indeed, 
GW4064 induced ALAS1 mRNA levels in a dose dependent manner (Fig. 3A). To 
further confirm the role of FXR in this pathway, primary human hepatocyte cultures 
were transiently transfected with a constitutively active form of FXR (VP16 huFXR), and 
subsequently challenged with GW4064 to achieve a maximal induction. As illustrated in 
Fig. 3B, VP16 huFXR alone or in combination with GW4064 significantly increased 
ALAS1 mRNA expression as well as the expression of the known FXR targets SHP 
and bile salt export pump (data not shown). These data further document the role of 
FXR in inducing ALAS1. 
FXR activation increases ALAS1 activity 
Having shown that activation of FXR increases ALAS1 transcripts we investigated in a 
next step whether the activity of the enzyme also was increased. ALAS1 activity was 
assayed after exposure of cultures with the drugs indicated in Fig. 4 in the presence of 
4,6-dioxoheptanoic acid (DHA), an inhibitor of aminolevulinic acid dehydratase, to 
prevent further usage of ALA. Phenobarbital, as well as natural and synthetic FXR 
agonists (50µM CDCA and 1µM GW4046), increased the activity of ALAS1 (expressed 
as nmole ALA produced per mg protein per hour) to similar levels. These data clearly 
show that not only mRNA levels of ALAS1 increase but also the corresponding protein 
and its activity.  
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Identification of a FXR responsive sequence in the 5’-flanking region of ALAS1 
Having established that ALAS1 mRNA as well as activity was induced upon FXR 
activation, we searched for putative FXR response elements in human ALAS1 gene. 
Therefore a combined in silico approach was chosen; a total of 67kb intergenic human 
ALAS1 sequence was filtered by cross species sequences comparison to retain only 
sequences, which are conserved between different species. Multispecies sequence 
alignments preformed by MULTIZ (Blanchette et al., 2004) resulted in the identification 
of a total of 16 blocks of conserved non-genic sequences, which then were individually 
scanned for putative FXR binding sites using NuibScan algorithm, specifically designed 
to detect nuclear receptors binding sites (Podvinec et al., 2002). Two conserved non-
genic sequences were found to contain high scoring FXR response elements (score > 
0.62), located at minus 14kb from the transcriptional start site and within intron 10 
respectively (called -14kb ALAS1 and ALAS1 intron). In order to see if the identified 
regions were able to confer a response to FXR, these regions were cloned in front of a 
thymidine kinase driven luciferase reporter construct for subsequent testing in CV-1 
transactivation assays. Since FXR response elements mostly have been characterized 
within the proximal promoter region, a construct encompassing 1.3kb of human ALAS1 
promoter was included in the analysis, although no putative FXRE was identified by 
NubiScan within the threshold used.  
As illustrated in Fig. 5B, CDCA increased the reporter activity of the -14kb ALAS1 in the 
presence of exogenous FXR. In contrast, the promoter construct as well as the 
construct spanning intron 10 were unaffected by CDCA treatment, indicating that the 
region at minus 14kb was able to confer a response to bile acids. To check if the 
response of the -14kb ALAS1 fragment to CDCA was FXR specific, the fragment was 
co-transfected with expression constructs of either FXR or PXR, in the absence or 
presence of PGC-1α, a coactivator also shown to co-activate various nuclear receptors 
including FXR (Zhang et al., 2004b). Again CDCA only augmented reporter gene 
activity of the -14kb ALAS1 fragment when FXR was present. This increase was FXR 
dependent, since the co-transfection of PXR had no effect on CDCA response of the 
fragment. As expected, the CDCA induction of reporter activity via FXR was further 
increased by PGC-1α up to 5-fold (Fig. 5C).  
In order to experimentally identify the exact sequences conferring the FXR response, 
the -14kb ALAS1 construct was digested and the resulting fragments were cloned into 
a reporter vector as illustrated in Fig. 6A. Subsequent testing in transactivation assays 
clearly showed (Fig. 6A), that a 175bp middle fragment (D) retained the response to 
CDCA in the presence of FXR with or without PGC-1α, while there was no significant 
response in the flanking fragments A and C. This middle region contains the IR1 
element initially reported by NUBIScan algorithm, showing a high similarity to known 
FXR bindings sites. The first halfsite is composed of a perfect nuclear receptor 
hexamer AGGTCA; the other halfsite is more degenerate with the sequence AGCCCC 
(Fig. 6). To demonstrate the importance of the identified IR1 in the FXR response, we 
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performed site directed mutagenesis as indicated. The response of the mutated 175bp 
fragment was robustly reduced as compared to the wildtype construct when stimulated 
with CDCA in the presence of FXR (Fig. 6C left panel). Moreover the activation of the 
175bp fragment by the constitutively active FXR (VP16 huFXR) was significantly 
reduced by the mutation (Fig. 6C right panel). These data clearly demonstrate that the 
identified region confers a specific response to FXR. We now describe another distal 
enhancer, in addition to the known CAR and PXR binding sites located at minus 21kb 
and minus 16kb (Podvinec et al., 2004), regulating ALAS1 transcription.  
 
The FXR/RXR heterodimer binds to the IR1 in the ALAS1 enhancer 
To assess whether an FXR-RXR heterodimer is able to bind to the newly identified IR1 
element, electromobility shift assays were performed using in vitro translated FXR and 
RXR together with 32P-labeled double stranded oligonucleotides derived from the 
responsive sequence (Table 1) and a perfect IR1 as a positive control. A specific DNA 
protein complex was formed when FXR and RXR were present in the binding reaction 
(Fig. 7: lane 4 and lane 15). Successful competition of the binding to the radiolabeled 
probe was achieved by adding cold oligonucleotide dimers of either human ALAS1 IR1 
or the perfect IR1 in increasing doses (25-200 fold excess) to the binding reaction (lane 
5-8 and lane 10-13). In contrast, no competition was observed, when the mutated IR1 
was used as a competitor (lane 9) demonstrating specificity of the binding. The addition 
of an antibody against FXR abolished the formation of a DNA protein complex at the 
ALAS1 IR1 and the perfect IR1 (lane 14 and lane16 in 7A and lane 3 in 7B), suggesting 
that this antibody targets a region in FXR essential for DNA binding or heterodimer 
formation. In contrast, an anti-RXR antibody successfully super-shifted the DNA protein 
complex (lane 2 in B). Taken together, these data indicate that the FXR/RXR 
specifically binds to the identified ALAS1 IR1. 
FXR activation of ALAS1 is ‘human specific’ and does not occur in mice 
To determine if FXR dependent induction of ALAS1 also occurs in rodents, C57Bl/6 
mice were treated with the FXR selective agonist GW4064. In livers form treated 
animals GW4064 significantly repressed not only CYP7a1 (data not shown), a well 
studied and characterized gene negatively regulated by FXR via SHP, but also ALAS1 
transcript levels (Fig. 8A). This inhibitory effect on ALAS1 was also seen when mice 
were fed a 1% cholic acid diet for 1 week (Fig. 8B). To exclude that the dissimilar 
findings in human liver culture systems and in vivo in mice were due to differences in 
experimental conditions, primary mouse hepatocytes were incubated with 50µM CDCA 
and analyzed for ALAS1 expression levels 8h later. Again, known FXR target gene 
SHP was markedly induced by CDCA treatment, while mouse ALAS1 transcript was 
significantly repressed (Fig. 8C). Taken together, these data show that both natural and 
synthetic FXR ligands affect hepatic ALAS1 levels in a species specific manner. 
Comparison of the homologous region of our newly identified human FXR response 
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element in the mouse genome demonstrated, that no putative IR1 element is present in 
mice (Fig. 8D). Even though the IR1 element is flanked by nucleotides showing high 
cross species sequence identity, the element itself is not conserved. The lack of 
conservation of a FXR response element therefore reflects the above described 
species specific regulation at the genomic nucleotide level.  
 
 
3.5 Discussion 
In the present study we identify human hepatic ALAS1 as a novel direct target of FXR. 
Both natural and synthetic agonists of FXR, CDCA and GW4064, were able to increase 
ALAS1 transcripts as well as activity in cultures of primary human hepatocytes. 
Treatment of human liver slices with near physiological concentration of CDCA also 
resulted in an increase in ALAS1 transcript levels. Moreover, by overexpression of a 
constitutively active form of FXR in primary human hepatocytes, the response of 
ALAS1 mRNA to GW4064 was significantly increased. In agreement with this, we 
identified and characterized in reporter assays a FXR response element in the 
5’flanking region of human ALAS1. Site directed mutagenesis experiments 
demonstrated the functionality of the IR1 element, and binding of FXR/RXR 
heterodimer was shown in gel shift experiments. These data suggest a role of bile acid 
activated FXR in the regulation of ALAS1 and consequently of hepatic heme and 
porphyrin synthesis. 
 
What is the physiological explanation for bile acids stimulating ALAS1? The rate limiting 
enzyme of heme synthesis is subject to various stimuli to adapt to ever changing 
demands of the cell for heme. More than 80% of hepatic heme is needed for 
incorporation into cytochromes P450, enzymes essential for detoxifying drugs and 
xenobiotics but also responsible for the synthesis and metabolism of endogenous 
substances, such as steroid hormones, cholesterol and bile acids (Guengerich, 2004). 
Cytochrome P450 CYP3A4 accounts for the metabolism of more than 50% of 
prescribed drugs, but is also a prerequisite for the hydroxylation and therefore 
detoxification of endogenous bile acids. The corresponding gene has been identified as 
a direct target of FXR only recently (Gnerre et al., 2004). This finding together with the 
identification of other FXR target genes involved in the elimination and metabolism of 
bile acids, such as UDP-glucuronosyltransferases (Barbier et al., 2003), 
sulfotransferases (Song et al., 2001), or transport proteins, such as MRP2 (Kast et al., 
2002), illustrate the central role of FXR in coordinating detoxification processes of 
potentially toxic bile acids. Since functional CYP3A4 requires heme as a prosthetic 
group, a sufficient supply of the hepatocytes with heme needs to be guaranteed, 
whenever bile acids accumulate. We now propose a model of coordinated induction of 
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apocytochrome CYP3A4 and heme synthesis conducted by FXR. Bile acid activated 
FXR simultaneously and directly stimulates the transcription of apoprotein as well as 
ALAS1 to ensure adequate amount of heme for incorporation into newly formed 
CYP3A4. A similar coordinated response upon drug treatment has been suggested for 
CAR and PXR (Podvinec et al., 2004); activated by drugs, CAR and PXR bind to 
response elements in the flanking region of members of the CYP3As and 2B families 
as well as to ALAS1 drug response elements. Hence ALAS1 is not only an essential 
accessory enzyme for detoxification of exogenous drugs but also of potentially toxic 
endogenous bile acids.  
Substantial crosstalk between the xenosensors CAR and PXR and bile acid receptor 
FXR has been established in the last years (Guo et al., 2003, Handschin and Meyer, 
2005, Zhang et al., 2004a). First, PXR itself is activated by bile acid precursors 
(Goodwin et al., 2003a) as well as by the secondary bile acid LCA and its metabolites 
(Staudinger et al., 2001, Krasowski et al., 2005). However, unlike FXR, PXR is not 
efficiently activated by primary bile acids (Krasowski et al., 2005). Second, the three 
nuclear receptors all repress bile acid synthesis, although via different mechanisms 
(Wang et al., 2002, Miao et al., 2006, Goodwin et al., 2000), and they share a common 
set of target genes involved in detoxification and elimination of toxic compounds from 
the body as mentioned above. And third, PXR has been found to be a direct target of 
FXR, further supporting the connection between these factors (Jung, D et al, 
submitted). Together, these findings lead to the model of a multifactorial and redundant 
detoxification system the liver has evolved to adapt to potentially toxic compounds. 
FXR activated by low or near physiological concentrations of primary bile acids 
represents the first line of defense, whereas toxic concentrations of bile acids in 
particular the secondary bile acid LCA push the response to a maximal level via CAR 
and PXR. We now add ALAS1 to the target genes, which are concomitantly regulated 
by CAR and PXR as well as FXR.  
Although overlapping substrate specificity for FXR and PXR have been reported, a 
pharmacological discrimination between the two nuclear receptors is possible. The 
induction of ALAS1 by a FXR specific pathway is underlined by the following data. First, 
low concentrations of CDCA, 10µM and 50µM, induced ALAS1 transcripts in human 
liver slices and cultures of primary hepatocytes, respectively. It is well established that 
these concentrations are unable to activate PXR. Despite earlier reports, where high 
concentration of CDCA (100µM) were found to activate PXR (Staudinger et al., 2001), 
CDCA was not found to have any potential to activate PXR in a recent detailed study 
(Krasowski et al., 2005). Second the specific FXR agonist GW4064 induced ALAS1, an 
effect, which was further augmented in the presence of exogenous FXR. In conclusion, 
these results strongly indicate an independent role of FXR in regulating ALAS1.  
The increase in ALAS1 mRNA upon FXR activation in two independent human 
experimental systems was not observed in mice. In contrast, FXR activation by 
GW4064 treatment, or by a 1% cholic acid diet for 1 week resulted in a significant 
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repression of hepatic ALAS1 transcripts in mice. This finding most likely was not due to 
the different experimental conditions between human (primary cells and liver slices) 
and rodents (in vivo), since treatment of primary mouse hepatocytes by CDCA also 
resulted in a suppression of murine ALAS1 transcripts. The mechanism underlying this 
species specific effect at this time remains purely speculative. Interestingly, the 
identified human IR1, even though flanked by sequences showing high cross species 
sequence identity, is not conserved in rodents, but rather seems to be a primate 
invention. This finding is consistent with the previous observations of the fast turnover 
of transcription regulatory sites during evolution (Emberly et al., 2003). Major 
differences between human and rodents in cholesterol and bile acids homeostasis are 
a well-established feature; the most prominent example is CYP7a1, which is positively 
regulated by cholesterol precursors via liver x receptor (LXR) in rodents but not 
humans (Chiang et al., 2001). Human specific targets of FXR have been previously 
described and include hepatic lipase (Sirvent et al., 2004), α-crystallin (Lee et al., 2005) 
and peroxisome proliferative receptor α (Pineda Torra et al., 2003). There is a rapidly 
growing number of pathways regulated by FXR (for a recent review: (Claudel et al., 
2005) (Houten et al., 2006), and the list is far from being complete. Future progress in 
this field should shed light into the species-specific response reported herein.  
Interestingly, our findings are consistent with a well known, although only incompletely 
understood clinical observation: Increased urinary porpyhrin excretion in humans is 
commonly seen in hepatobiliary diseases accompanied by cholestasis (Rocchi et al., 
2005, Doss M, 1972) (Gibson et al., 2000). Impaired biliary excretion of porphyrins in 
these conditions is one obvious explanation. In humans the main bile acid retained in 
cholestasis is CDCA. We now identified CDCA as a potent inducer of human ALAS1, 
which may imply that increased porphyrin synthesis in cholestatic conditions 
contributes to the phenomenon of elevated urinary porphyrin excretion as it has 
previously been suggested (Rocchi et al., 2005, Doss M, 1972). Analysis of porphyrin 
precursors in the urine of cholestatic patients could test this hypothesis. 
The clinical implications of the data reported here are the situations where ALAS1 is 
more sensitive to induction, as in acute hepatic porphyrias. Due to a relative heme 
deficiency, the negative feedback exerted by heme on ALAS1 is reduced, and 
synthesis is rapidly and excessively stimulated whenever ALAS1 is activated. Known 
triggering factors include drugs that induce P450 hemeproteins, alcohol, fasting, sex 
steroids and all forms of stress. However the triggering events of most acute attacks 
remain obscure. It has long been assumed that ALAS1 is only indirectly upregulated via 
a diminishing regulatory heme pool upon heme consuming stimuli (Thunell, 2000, May 
et al., 1995). However, in our previous studies we established that several precipitating 
factors directly upregulate ALAS1 at the transcriptional level. Phenobarbital type drugs 
stimulate ALAS1 via xenosensing nuclear receptors PXR and CAR acting through two 
distal enhancer elements (Podvinec et al., 2004). The coactivator PGC-1α drives the 
fasting response via one FOXO1 site (Handschin et al., 2005) probably in concert with 
a c-AMP response (Giono et al., 2001) within the proximal promoter of ALAS1. With the 
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identification of a novel enhancer element conferring a FXR specific response of 
ALAS1, we here describe an additional mechanism having the potential to trigger acute 
porphyric attacks.  
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3.6 Figures 
 
Figure 1:  Bile acids induce ALAS1 mRNA level in cultured primary human hepatocytes. 
  Cultures of primary human hepatocytes were prepared and plated as described 
under materials and methods. After 24h incubation in serum free conditions, cells 
were challenged in (A) with vehicle (DMSO 0.1%), 50µM chenodeoxycholic acid 
(CDCA), 500µM phenobarbital (PB) or CDCA and PB in combination and in (B) with 
the primary bile acids CDCA, cholic acid (CA), ursodeoxycholic acid (UDCA; all at 
50µM) and the secondary bile acid 25µM lithocholic acid (LCA). 8h later, RNA was 
isolated and ALAS1 mRNA expression relative to 18S was determined. A) ALAS1 
mRNA expression is increased by its classical inducer PB as well as by the primary 
bile acid CDCA. The combination of both further increases the response. B) Different 
primary bile acids CDCA, CA, UDCA and the secondary bile acid LCA all induced  
ALAS1 and SHP mRNA expressions to various degrees. Values are given as mean 
+/- SD of duplicates with vehicle set at 1. The data presented are representative of 
the results from 2 different donors.  
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Figure 2:  Chenodeoxycholic acid induces ALAS1 mRNA expression in human liver slices 
  Human liver slices were prepared as described under materials and methods. Slices 
of three different donors A, B and C were incubated with either vehicle (0.1% 
DMSO), 10µM and 100µM chenodeoxycholic acid (CDCA). After 8h, 16h and 24h 
treatment, RNA was extracted and expression levels for ALAS1 relative to 
cyclophilin were determined. 
  ALAS1 mRNA expression was increased upon CDCA treatment in slices of all three 
donors tested. Individual variety with respect to basal ALAS1 mRNA expression, the 
time course of response and the fold increase upon CDCA treatment are illustrated. 
Highest ALAS1 mRNA levels were achieved upon 100µM CDCA in donor A after 
16h, in donor B and C after 24h. The low and near physiological concentration of 
10µM CDCA was sufficient to increase ALAS1 transcripts in donor A (16h and 24h), 
donor B (16h and 24h) and donor C (24h). Values are given as means of PCR 
duplicates for each donor separately. 
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Figure 3:  Activation of FXR induces ALAS1 mRNA expression in cultures of primary human 
hepatocytes. 
  Cultures of primary human hepatocytes were plated and treated as in Fig. 1, except 
that the specific FXR agonist GW4064 was used from 10nM to 5µM. A) GW4064 
induces ALAS1 in a dose dependent manner. Values are given as mean +/- SD of 
duplicate samples. The data presented is representative of the results from 2 
different donors. B) After overnight plating, primary human hepatoytes were 
transfected with VP16 human FXR or a control plasmid. 36h later cells were induced 
with either vehicle or 1µM GW4064 for 8h when RNA was isolated and ALAS1 
mRNA expression relative to cyclophilin was determined. Overexpression of VP16 
FXR increased the mRNA level of ALAS1 and further increased the induction of 
ALAS1 by 1µM GW4064. Values are given as mean +/- SD of triplicate samples. * 
and ** indicate p<0.05 and p<0.01 respectively VP16 FXR versus vector control. # 
indicates p<0.01 GW4064 versus vehicle control. 
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Figure 4:  FXR activation increases ALAS activity in cultures of primary human hepatocytes 
  Cultures of primary human hepatocytes were prepared and plated as described 
under materials and methods. After 12h incubation in serum free medium, cells were 
exposed overnight to vehicle (0.15% DMSO), 250µM 4,6-dioxoheptanoic acid (DHA) 
alone or together with 50µM chenodeoxycholic acid (CDCA), 1µM GW4064 or 
500µM Phenobarbital (PB).  ALAS activity was assayed in culture plates for 2hrs, 
and the supernatants were prepared and analyzed for ALA production as described 
under materials and methods. Values are expressed as nmol ALA produced per mg 
protein per hour and given as mean +/- SD of duplicate samples. The data 
presented are representative of the results from 2 different donors. 
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Figure 5:  Identification of a FXR Response Element (FXRE) in the 5’-flanking region of human 
ALAS1  
  A) Schematic representation of human ALAS1 gene. NubiScan identified two high 
scoring IR1 elements within cross species conserved non-genic sequences, located 
at minus 14kb and within intron 10 respectively. The 1.3kb spanning promoter 
construct used in (B) is shown in white box.  
  B) The -14kb ALAS1 construct confers a FXR response. CV1 cells were co-
transfected with the ALAS1 -14kb, 1.3kb ALAS1 promoter or the ALAS1 intron 
construct, together with expression plasmids of huFXR or vector control. 24h later, 
cells were treated with vehicle (0.1% DMSO) or 50µM CDCA and analyzed for 
luciferase light units relative to β-galactosidase after 24h. CDCA in the presence of 
FXR increased the reporter activity of the -14kb ALAS1 construct but not 1.3kb 
promoter nor ALAS1 intron. 
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 C) PGC1α coactivates CDCA response to FXR at the -14kb ALAS1. CV1 cells were 
co-transfected with the -14kb ALAS1 together with expression plasmids of huFXR or 
huPXR with or without huPGC1α. 24h later, cells were treated with vehicle (DMSO 
0.1%) or 50µM CDCA and analyzed for luciferase light units relative to β-
galactosidase 24h later. CDCA increased reporter activity of the -14kb ALAS1 only 
in the presence of FXR, and not PXR. Co-transfection of FXR with PGC1α resulted 
in maximal response. Values are given as mean +/- SD. All transfections were 
performed in at least 3 to 4 different experiments in duplicates or quadruplicates. ** 
p<0.01 indicates CDCA versus vehicle control. # and ## indicate p<0.05 and p<0.01 
respectively. 
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Figure 6:  Characterization of a functional IR1 within the 795bp FXRE 
  A) Subcloning of the -14kb ALAS1 construct. CV1 cells were co-transfected with the  
parental 795bp construct and the subfragments A, B, C and D as illustrated together 
with expression plasmids of huFXR with or without huPGC1α. 24h later, cells were 
treated with vehicle (DMSO 0.1%) or 50µM CDCA and analyzed for luciferase light 
units relative to β-galactosidase 24h later. The 175bp middle fragment D retained 
the response to CDCA and PGC-1α in the presence of FXR, while there was no 
significant response observed in the flanking fragment A and C.  
  B) Sequence of 175bp fragment with the identified IR1 element shown in bold. The 
ALAS1 IR1 shows high similarity to the known FXR response element in the ileal bile 
acid binding protein (IBABP) promoter.  
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  C) Site directed mutagenesis of the IR1. CV1 cells were transfected with wildtype or 
mutated 175bp fragment together with expression constructs for FXR and PGC1α 
and subsequently stimulated with CDCA as in (A) (left panel) or CV1 cells were co-
transfected with the constitutively active VP16 FXR (right panel). Mutation of halfsite 
1 to TCTAGA resulted in a significant loss of the FXR response to CDCA and 
PGC1α (left panel) as well as to VP16 huFXR (right panel). Values are given as 
mean +/- SD. All transfections were performed in at least 2 to 4 different 
experiments. * and ** indicate p<0.05 and p<0.01 respectively CDCA versus vehicle 
control. ## indicates p<0.01 wildtype versus mutated fragment. 
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Figure 7:  FXR/RXR heterodimer binds to the IR1 element of human ALAS1 
  EMSA assays were performed using the radiolabeled probes of human ALAS1 (huA 
IR1) (lane 1-14 in A and lane 1-3 in B) or a perfect IR1 (p IR1) (lane 15-16). The 
sequences of the wildtype and mutated probes are listed in Table 1.  
  A) FXR/RXR heterodimer binds to huA IR1 with high affinity (lane 4). The protein 
DNA complex disappears with increasing doses of competing wildtype unlabeled 
probe (lane 5-8), or unlabeled perfect IR1 (lane 10-13), but not with mutated huA IR1 
(lane 9). An antibody against human FXR blocks the formation of a FXR/RXR DNA 
complex at huA IR1 and at p IR1 (lane 14 and 16 in A and lane 3 in B) 
  B). The FXR/RXR complex is successfully supershifted by an antibody against RXR 
(lane 2 in B).  
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Figure 8:  FXR activation of ALAS1 is ‘human specific’ and does not occur in mice  
  FXR activation by GW4064 or by cholic acid feeding represses hepatic ALAS1 in 
mice.  
  A) C57Bl/6 mice were injected with 40mg/kg GW4064 (i.p.), sacrificed 16hrs later, 
when the livers were excised and analyzed for ALAS1 mRNA expression relative to 
GAPDH.  
  B) C57Bl/6 mice were fed normal chow or a 1% cholic acid diet for 1 week. Relative 
mRNA levels for hepatic ALAS1 were determined as in (A). n = 4-5 animals per 
group. * and ** indicate p<0.05 and p<0.01 resp. treated versus untreated control.  
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  C) Primary mouse hepatocytes were isolated as described under material and 
methods. After culturing the cells 24h in serum free conditions, cultures of primary 
mouse hepatocytes were incubated with either vehicle or 50µM CDCA for 8h, when 
RNA was extracted and mRNA levels of SHP and ALAS1 relative to GAPDH were 
determined. Values are given as mean +/- SD of triplicate samples. ** indicates 
p<0.01 CDCA versus vehicle control.  
  D) Multispecies (human, chimpanzee, rhesus, rabbit, mouse, rat, dog and cow) 
sequence alignment produced by MULTIZ covering the characterized human IR1 
element was retrieved from Santa Cruz Genome Browser. The IR1 element is 
conserved only in primate species and not present in mice.  
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Table 1:  Sequences used for real time PCR, cloning, EMSA and mutagenesis. Only the 
sense strands are shown for oligonucleotides used in EMSA assays.  
Gene/name Primers Purpose 
h18S  5’-AGTCCCTGCCCTTTGTACACA-3’ F 
5’-CGATCCGAGGGCCTCACTA-3’ R 
5’-CGCCCGTCGCTACTACCGATTGG-3’ Probe 
RT-PCR, 
Taqman 
hCyclophilin 5’-GGAGATGGCACAGGAGGAA-3’ F 
5’-GCCCGTAGTGCTTCAGCTT-3’ R 
RT-PCR, 
SYBR 
hALAS1 5’-ATGATGCCAGGCTGTGAGATTT-3’ F 
5’-GCTGTTTCGAATCCCTTGGA-3’ R 
5’-TCTGATTCTGGGAACCATGCCTCCA-3’ Probe 
RT-PCR, 
Taqman 
hSHP 5’-CTTCAATGCTGTCTGGAGTCCTT -3’ 
5’-GCACCAGGGTTCCAGGACTT-3’ 
RT-PCR, 
SYBR 
hBSEP 5’-CAGTTCCCTCAACCAGAACATG-3’ F 
5’-TTTGATCATTTCGCTCTCGATG-3’ R 
RT-PCR, 
SYBR 
mGAPDH 5’-CCAGAACATCATCCCTGCATC-3’ F 
5’-GGTCCTCAGTGTAGCCCAAGAT-3’ R 
5’-CCGCCTGGAGAAACCTGCCAAGTATG-3’ Probe 
RT-PCR, 
Taqman 
mALAS1 5’-GGCCTCCCGGTCATCC-3’ F 
5’-TGTTCTTAGCAGCATCGGCA-3’ R 
5’-CTGTCCGAGTCACATCATCCCTGTGC-3’ Probe 
RT-PCR, 
Taqman 
mSHP 5’-TGAGCTGGGTCCCAAGGA-3’  F 
5’-AGGGCTCCAAGACTTCACACA-3’ R 
RT-PCR, 
SYBR 
1.3kb prom 
ALAS1 
5’- cgGGTACCGAGCTCTCAGACCAAAGCCC  -3’ F 
5’- ccgCTCGAGCAAGTCGAGAAGTCCAAACG -3’ R 
Cloning 
-14kb 
ALAS1 
5’-cgGGTACCGGTGGAGAATCTGAGGTCCA -3’ F 
5’-ccgCTCGAGCTCTTCCTTGACCACCACCT-3’ R 
Cloning 
Intron10 
ALAS1 
5’- cgGGTACCAATGGCCTGTCTCTGATTGG -3’ F 
5’- ccgCTCGAGGCCTCTGAAGGGCTTCAATTA -3’ R 
Cloning 
Mut IR1 5’-
CATGTGTGCCTCTGTGACATCTAGACAGCCCCCGAGGCA
CGC-3’ 
Mutagenesis 
hA IR1 5’-TGTGACAAGGTCACAGCCCCCGAGGCA-3’ EMSA 
hA mt IR1 5’-TGTGACATCTAGACAGCCCCCGAGGCA-3’ EMSA 
Perfect IR1 5’-GCTTTTAGGTCAATGACCTAGCCCTC-3’ EMSA 
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Summary
Inducible hepatic porphyrias are inherited genetic dis-
orders of enzymes of heme biosynthesis. The main clin-
ical manifestations are acute attacks of neuropsy-
chiatric symptoms frequently precipitated by drugs,
hormones, or fasting, associated with increased uri-
nary excretion of -aminolevulinic acid (ALA). Acute
attacks are treated by heme infusion and glucose ad-
ministration, but the mechanisms underlying the pre-
cipitating effects of fasting and the beneficial effects
of glucose are unknown. We show that the rate-limit-
ing enzyme in hepatic heme biosynthesis, 5-amino-
levulinate synthase (ALAS-1), is regulated by the per-
oxisome proliferator-activated receptor  coactivator
1 (PGC-1). Elevation of PGC-1 in mice via adeno-
viral vectors increases the levels of heme precursors
in vivo as observed in acute attacks. The induction
of ALAS-1 by fasting is lost in liver-specific PGC-1
knockout animals, as is the ability of porphyrogenic
drugs to dysregulate heme biosynthesis. These data
show that PGC-1 links nutritional status to heme
biosynthesis and acute hepatic porphyria.
Introduction
The heme biosynthetic pathway in eukaryotic cells is
comprised of eight enzymatic steps; the first and the
last three enzymes are located in the mitochondria,
while the rest are in the cytoplasm (Figure 1A). Eighty
to ninety percent of total heme in mammals is synthe-
sized in erythroid cells for incorporation into hemoglo-
bin. Regulation of heme biosynthesis in these cells in-
volves the erythroid-specific aminolevulinate synthase
(ALAS) gene ALAS-2. In contrast, the housekeeping
ALAS gene ALAS-1, also called ALAS-N or ALAS-H, is
ubiquitously expressed, given that all nucleated cells
must synthesize heme for respiratory cytochromes. The
bulk of the nonerythroid-synthesized heme is produced
in the liver for various heme proteins, in particular*Correspondence: bruce_spiegelman@dfci.harvard.edu
3This paper is dedicated to the memory of our dear colleague and
friend, Stanley J. Korsmeyer.microsomal cytochromes P450. Because either a defi-
ciency or an excess of heme is toxic to the cell, hepatic
heme production has to be tightly controlled, mostly
via its rate-limiting step ALAS-1. Accordingly, hepatic
ALAS-1 is highly regulated in different contexts to en-
sure adequate levels of intracellular heme (May et al.,
1995). Inherited mutations in all genes encoding for
heme biosynthetic enzymes have been described, ex-
cept for ALAS-1, and the resulting diseases are referred
to as porphyrias (Elder, 1998). Depending on the spe-
cific enzymatic defect, different patterns of overpro-
duction, accumulation, and excretion of intermediates
of heme synthesis are observed.
The main clinical manifestations of porphyrias are in-
termittent attacks of neuropsychiatric dysfunction and/
or sensitivity of the skin to sunlight. The neuropsychiat-
ric syndrome occurs only in those porphyrias in which
there is intermittent induction of hepatic ALAS-1 and
consequent increased urinary excretion of δ-aminolev-
ulinic acid (ALA). Attacks are characteristically precipi-
tated by drugs such as barbiturates, fasting, and hor-
mones and result in abdominal pain, tachycardia,
peripheral motor neuropathies, psychosis, and other
mental disturbances (Elder, 1998; Thadani et al., 2000;
Thunell, 2000). Inducible hepatic porphyrias are caused
by rare defects in δ-aminolevulinic acid dehydratase
(ALAD), porphobilinogen deaminase (PBGD, also known
as hydroxymethylbilane synthase), coproporphyrinogen
oxidase, and protoporphyrinogen oxidase. The classical
names for the corresponding diseases are ALAD defi-
ciency, acute intermittent porphyria, hereditary copropor-
phyria, and variegate porphyria.
Although not definitively proven, historic personali-
ties thought to have suffered from porphyria include
King George III (Macalpine and Hunter, 1966), Friedrich
Wilhelm I of Prussia (Macalpine et al., 1968; Pierach
and Jennewein, 1999), and Vincent van Gogh (Bonkov-
sky et al., 1992; Loftus and Arnold, 1991). Thus, the
psychoses arising from their disease potentially influ-
enced the course of the American war for indepen-
dence and/or the creative genius of van Gogh. Acute
attacks of inducible hepatic porphyria are treated by
discontinuing exposure to the precipitating agents,
heme infusions, and high carbohydrate load. The car-
bohydrates are typically given as concentrated glucose
infusion. Heme directly represses its own biosynthesis
in a negative feedback loop (May et al., 1995). In con-
trast, the underlying mechanisms of the beneficial ef-
fects of carbohydrates are not understood.
Proliferator-activated receptor γ coactivator 1α (PGC-
1α) is a coactivator of nuclear receptors and other tran-
scription factors (Puigserver and Spiegelman, 2003).
PGC-1α controls mitochondrial biogenesis and oxida-
tive metabolism in many tissues, including brown adi-
pose tissue, skeletal muscle, heart, and liver (Lehman
et al., 2000; Puigserver et al., 1998; Wu et al., 1999;
Yoon et al., 2001). In the liver, PGC-1α is induced during
fasting, when the liver ceases using glucose as an en-
ergy supply and changes to the β-oxidation of fatty
Cell
506
43Figure 1. ALAS-1 Expression Is Activated by PGC-1α in Hepatocytes and Liver In Vivo
(A) Heme biosynthesis pathway. ALA, 5-aminolevulinic acid; ALAD, ALA dehydratase; PBG, porphobilinogen; PBGD, PBG deaminase; HMB,
hydroxymethylbiline; Uro-P, uroporphyrinogen; Copro-P, coproporphyrinogen; Cpo, coproporphyrinogen oxidase; Proto-P, protoporphy-
rinogen.
(B) ALAS-1 and PGC-1α mRNAs are coinduced in fasting. Mice were fasted for 6 hr and 24 hr, respectively, and hepatic levels of PGC-1α
and ALAS-1 were compared to those of fed and refed animals by semiquantitative PCR.
(C and D) Adenoviral PGC-1α increases ALAS-1 gene expression in cell culture. Fao rat hepatoma cells (C) and mouse primary hepatocytes
(D) were infected with adenovirus encoding GFP or PGC-1α, respectively, and relative mRNA levels of PGC-1α, glucose-6-phosphatase
(Glc6P), and ALAS-1 were determined by semiquantitative PCR 24 hr after infection.
(E) PGC-1α induces ALAS-1 transcript levels in vivo. Male Wistar rats were tail-vein injected with adenovirus encoding for GFP and PGC-1α,
respectively. Five days postinjection, animals were sacrificed, and hepatic mRNAs were analyzed for changes in expression using semiquanti-
tative PCR. Data in (B)–(E) are represented as mean ± standard deviation.acids. This increase in fatty-acid β-oxidation and eleva-
tion of hepatic gluconeogenesis are both under control
of PGC-1α (Herzig et al., 2001; Yoon et al., 2001).
Thus, because of the key role of PGC-1α in liver en-
ergy homeostasis and the finding that many PGC-1α
t
P
b
t
aargets are heme proteins, we investigated the role of
GC-1α in the regulation of hepatic heme biosynthesis
y nutrition. We found that PGC-1α is an important fac-
or controlling the expression of ALAS-1 in the fasted
nd fed liver. Moreover, we showed that hepatic PGC-
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441α is a major determinant of the severity of acute
porphyric attacks in mouse models of chemical por-
phyria.
Results
Hepatic PGC-1 and ALAS-1 Are Coregulated
in Fasting and Feeding
Since fasting can be a powerful stimulus to induce an
acute porphyric attack and the liver is central to the fast-
ing response in mammals, the metabolic status of the
liver should be crucial for the regulation of heme biosyn-
thesis. The transcriptional coactivator PGC-1α has been
described as a key factor in the control of hepatic gluco-
neogenesis in the fasted liver (Herzig et al., 2001; Yoon
et al., 2001). Interestingly, ALAS-1 and PGC-1α are cor-
egulated in fasted mice, with increased mRNA levels
(Figure 1B). To test the relationship between the regula-
tion of these two genes, Fao rat hepatoma cells, mouse
primary hepatocytes, and rat liver in vivo were infected
with adenovirus expressing PGC-1α. In all of these sys-
tems, ectopic expression of PGC-1α increased ALAS-1
transcript levels in a manner similar to that of glucose-
6-phosphatase (Glc6P), a PGC-1α target gene involved
in gluconeogenesis (Yoon et al., 2001) (Figures 1C–1E).
In contrast to ALAS-1, none of the other seven genes
of the heme biosynthetic pathway were induced by
PGC-1α in rat liver (Figure 1E).
Insulin and Glucagon Regulation of ALAS-1
Involves PGC-1
Regulation of ALAS-1 in fasting and feeding is medi-
ated by the counterregulatory hormones insulin and
glucagon (Scassa et al., 1998; Varone et al., 1999). Insu-
lin treatment of primary mouse hepatocytes reduces
basal levels of ALAS-1 mRNA (Figure 2A). Furthermore,Figure 2. ALAS-1 Expression Is Regulated by
PGC-1α and Insulin
(A) Insulin represses PGC-1α-mediated in-
duction of ALAS-1. H2.35 SV-40-transformed
hepatocyte cells were infected with adenovi-
ral GFP and PGC-1α for 24 hr and subse-
quently treated with vehicle (PBS) or 10 nM
insulin for 12 hr before relative ALAS-1, cyto-
chrome c, and PGC-1α mRNA levels were
determined. *p < 0.05 between vehicle- and
insulin-treated cells.
(B) ALAS-1 induction by dexamethasone and
forskolin is partially dependent on PGC-1α.
Mouse primary hepatocyte cultures were
established from wild-type and PGC-1α total
knockout animals. These cells were subse-
quently treated with dexamethasone (Dex, 1
M) and forskolin (Forsk, 0.2 M) for 3 hr,
and relative mRNA levels were determined
by semiquantitative PCR. Data in (A) and (B)
are represented as mean ± standard devia-
tion. *p < 0.05 between wild-type and knock-
out cells in Student’s t test.PGC-1α-induced ALAS-1 transcript levels are reduced
by insulin, suggesting that PGC-1α is in the pathway
of the insulin regulation of ALAS-1 (Figure 2A). Primary
hepatocytes from wild-type and PGC-1α knockout
mice (Lin et al., 2004) were used to elucidate the func-
tion of PGC-1α in the ALAS-1 induction in fasting, with
dexamethasone and forskolin representing the effects
of glucocorticoids and glucagon that are elevated when
blood glucose levels are low. Induction of ALAS-1
mRNA by these agents was reduced in the PGC-1α
knockout hepatocytes as compared to wild-type cells
(Figure 2B). Similarly, the response of the gluconeogenic
genes phosphoenolpyruvate carboxykinase (PEPCK) and
Glc6P to these hormones was blunted. These findings
imply that PGC-1α is involved in the fasting/feeding
regulation of all three genes.
Insulin Repression of ALAS-1 Is Mediated
by FOXO1 and PGC-1
In the ALAS-1 promoter, two binding sites for the
nuclear respiratory factor-1 (NRF-1) have been iden-
tified (Braidotti et al., 1993). NRF-1 is a transcription
factor that increases expression of nuclear-encoded
mitochondrial genes (Virbasius and Scarpulla, 1994)
and is known to be potently coactivated by PGC-1α
(Wu et al., 1999). Thus, NRF-1 is a potential binding
partner by which PGC-1α controls ALAS-1 expression.
In addition to the NRF-1 site, an insulin-responsive ele-
ment (IRE) has been defined in the ALAS-1 promoter
(Scassa et al., 2001, 2004), but the identity of transcrip-
tion factors binding to this element has remained elu-
sive (Figure 3A).
Chromatin immunoprecipitation assays in mouse
hepatoma cells illustrate that PGC-1α is recruited to
both the NRF-1 and the IRE regions (Figure 3B). More-
over, PGC-1α recruitment to the IRE region is sensitive
Cell
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45Figure 3. PGC-1α Regulates ALAS-1 Expression via NRF-1 and
FOXO1
(A) Structure of the ALAS-1 promoter.
(B) PGC-1α binds to the NRF-1 and the IRE sites on the ALAS-1
promoter. H2.35 cells were infected with adenoviral GFP or FLAG-
tagged PGC-1α. Cells were treated with 10 nM insulin for 12 hr
before cells were harvested and chromatin immunoprecipitation
was performed using an anti-FLAG antibody.
(C) PGC-1α coactivates FOXO1 on the ALAS-1 promoter. H.35 cells
were transfected with ALAS-1-promoter construct and expression
plasmids for FOXO1, HNF3α (FOXA1), HNF3β (FOXA2), and PGC-
1α. After transfection, cells were treated with 10 nM insulin for 12
hr before reporter-gene levels were determined. Data are repre-
sented as mean ± standard deviation.
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cto insulin, in contrast to PGC-1α binding to the NRF-1
site (Figure 3B). Sequence comparison of the ALAS-1
IRE to those of the gluconeogenic genes PEPCK and
Glc6P revealed high sequence conservation between
these sites. In the flanking regions of the gluconeogenic
genes, PGC-1α binds to FOXO1 at these elements. Af-
ter insulin exposure, FOXO1 is phosphorylated, its bind-
ing to PGC-1α disrupted, and, subsequently, FOXO1 is
exported from the nucleus (Puigserver et al., 2003).
Thus, FOXO1 is a plausible candidate to bind to the
ALAS-1 promoter.
Recently, Scassa and coworkers described the hepa-
tocyte nuclear factor 3β (HNF3β, alternatively called
FOXA2) to bind to sites adjacent to the ALAS-1 IRE
(Scassa et al., 2004) (Figure 3A). They found that integ-
rity of the IRE and not of the HNF3β sites is obligatory
for insulin regulation of ALAS-1 and that the regulation
of ALAS-1 by HNF3β cannot account for the repression
of ALAS-1 by insulin (Scassa et al., 2004). We thus
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cested the ability of PGC-1α to coactivate the different
orkhead box family members FOXO1, hepatocyte
uclear factor 3α (HNF3α, FOXA1), and HNF3β on the
LAS-1 promoter. As described by Scassa et al.,
NF3β increased reporter-gene levels controlled by the
LAS-1 promoter, whereas HNF3α had no effect (Figure
C). However, of the three transcription factors, PGC-
α only coactivated FOXO1 in this context. In addition,
erely the FOXO1-PGC-1α-mediated induction of the
LAS-1 promoter was repressed by insulin (Figure 3C).
To further characterize the role for FOXO1 in the regu-
ation of the ALAS-1 promoter, we showed direct physi-
al interaction of FOXO1 with the DNA probes contain-
ng the ALAS-1 IRE (Figure 4A, lanes 4–7) and NRF-1
ith the NRF-1 site (Figure 4A, lanes 1–3) in electropho-
etic mobility shift assays. Site-directed mutagenesis of
he FOXO1 site abolished binding of FOXO1 to this ele-
ent (Figure 4A, lanes 3 and 7, respectively). The speci-
icity of the FOXO1-IRE complex was confirmed by using
n anti-FOXO1 antibody that resulted in a supershift (Fig-
re 4A, lane 6). Functionally, PGC-1α coactivates both
RF-1 and FOXO1 in reporter-gene assays using the
LAS-1 promoter in mouse H2.35 SV-40-transformed
epatocytes (Figure 4B). Mutagenesis of the NRF-1 or
he IRE sites reduced the ability of PGC-1α to augment
he activity from the ALAS-1 promoter stimulated by
RF-1 and FOXO1, respectively. Moreover, an ALAS-1-
romoter allele with a combined mutation of both the
RF-1 and IRE sites is completely insensitive to PGC-
α, strongly suggesting that NRF-1 and FOXO1 are the
ajor binding partners of PGC-1α in the ALAS-1 pro-
oter.
As shown in Figure 4C, insulin represses induction of
LAS-1-promoter-driven reporter-gene expression by
ither FOXO1 alone or in combination with PGC-1α. In
ontrast, a nonphosphorylatable mutant of FOXO1 with
hree alanines in place of the serine/threonine residues
argeted by Akt kinase (termed FOXO1 3A) prevented
epression by insulin. Similarly, insulin is unable to in-
ibit PGC-1α coactivation of FOXO1 3A. This suggests
hat the insulin repression of the ALAS-1 promoter is
ontrolled by the FOXO1-PGC-1α interaction.
iver-Specific PGC-1 Knockout Animals Have
Blunted Induction of ALAS-1 in Fasting
o investigate whether PGC-1α is a key mediator of the
etabolic regulation of ALAS-1 in an in vivo setting, we
irst examined animals with a total knockout of PGC-1α
Lin et al., 2004) under fasting and feeding conditions.
nfortunately, regulation of ALAS-1 is masked by sys-
emic effects of the whole-body knockout of PGC-1α,
imilar to what has previously been described for the
luconeogenic genes (Lin et al., 2004): ALAS-1 mRNA
s constitutively induced to fasted levels in the total
nockout animals, even in the fed state (Figure 5A). It is
nclear whether the same compensatory mechanisms
elevation of C/EBPβ) account for the constitutive ex-
ression of the gluconeogenic genes and ALAS-1 (Lin
t al., 2004). Thus, in order to dissect systemic effects
f the total knockout from the liver phenotype, we had
o generate liver-specific PGC-1α knockout animals by
rossing mice with a floxed PGC-1α allele to transgenic
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46Figure 4. FOXO1-PGC-1α Mediate the Re-
pression of the ALAS-1 Promoter by Insulin
(A) FOXO1 binds to the ALAS-1 promoter.
Electrophoretic mobility shift assays were per-
formed using radiolabeled wild-type and mu-
tated ALAS-1 promoter as probe together
with in vitro-transcribed/translated NRF-1
and FOXO1, respectively.
(B) PGC-1α induction of the ALAS-1 promoter
is mediated by NRF-1 and FOXO1. H2.35
cells were transfected with wild-type and
ALAS-1-promoter constructs with mutations
in the NRF-1 and the IRE sites together with
expression plasmids for PGC-1α, NRF-1,
and FOXO1. Reporter-gene levels were de-
termined 16 hr after transfection.
(C) Insulin regulation of the ALAS-1 promoter
is inhibited by a mutant FOXO1 allele. H2.35
cells were transfected with a reporter-gene
plasmid driven by the wild-type ALAS-1
promoter together with expression plasmids
for PGC-1α, FOXO1, and FOXO1 3A, a
FOXO1 allele that is not phosphorylated by
insulin signaling. After transfection, cells
were treated with 10 nM insulin for 12 hr be-
fore reporter-gene levels were determined.
Data in (B) and (C) are represented as mean ±
standard deviation. *p < 0.05 between vehi-
cle- and insulin-treated cells in Student’s t
test.animals expressing cre recombinase under the control
of the albumin promoter (Figure 5B). Tissue-specific
ablation of PGC-1α in the liver was verified by mRNA
analysis (Figure 5C). PGC-1α levels in the heart, skele-
tal muscle (SKM), and brown adipose tissue (BAT) were
unaltered. Moreover, liver-specific knockout of PGC-1α
did not change the expression of the closely related
family member PGC-1β in liver, heart, skeletal muscle,
or brown adipose tissue.
In these mice, basal levels of ALAS-1, PEPCK, and
Glc6P were not elevated, as was seen in the total knock-
out (Figure 5D). Indeed, ALAS-1 basal expression was
significantly lower in the liver-specific PGC-1α knock-
out as compared to wild-type animals. Moreover, the
induction of ALAS-1 and the gluconeogenic genes after
16 hr of fasting was severely blunted in the liver-spe-cific knockout animals compared to wild-type mice
(Figure 5D). These findings indicate a requirement for
PGC-1α in the fasting/feeding regulation of the gluco-
neogenic genes and, furthermore, imply a key role for
PGC-1α in the dietary control of ALAS-1 transcription.
Patients suffering from porphyric attacks are given a
high carbohydrate load. Thus, in addition to refeeding,
fasted mice were i.p. injected with a bolus of glucose
(1 g/kg) or glucose (1 g/kg) and insulin (1.0 U/kg) 30
min, 60 min, or 120 min before mice were sacrificed
and hepatic PGC-1α and ALAS-1 mRNA levels were de-
termined (Figure 5E). Glucose loading reduces ALAS-1
transcript levels 30 min after injection. The combination
of glucose and insulin is even more potent in inhibiting
fasting-mediated induction of PGC-1α and ALAS-1,
supporting the hypothesis that at least part of the bene-
Cell
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47Figure 5. Fasting-Mediated Induction of ALAS-1 Is Drastically Reduced in a Liver-Specific PGC-1α Knockout Model
(A) Hepatic ALAS-1 is constitutively increased in fasting and feeding in PGC-1α total knockout mice. PGC-1α total knockout animals were
fasted for 12 hr before relative mRNA levels for PGC-1α, ALAS-1, and phosphoenolpyruvate carboxykinase (PEPCK) were determined.
(B) Generation of liver-specific PGC-1α knockout animals. Mice with a floxed PGC-1α allele were crossed with animals that transgenically
express cre recombinase under the control of the albumin promoter.
(C) Hepatic expression of PGC-1α is absent in the liver-specific knockout animals. Different tissues were harvested from wild-type and
knockout mice, and relative PGC-1α and PGC-1β levels were determined by semiquantitative PCR. SKM, skeletal muscle; BAT, brown adi-
pose tissue.
(D) Absence of PGC-1α abolishes ALAS-1 induction in the liver by fasting. Wild-type and liver-specific PGC-1α knockout mice were fasted
for 12 hr, and relative transcript levels for PGC-1α, ALAS-1, PEPCK, and glucose-6-phosphatase (Glc6P) were determined by semiquantita-
tive PCR.
(E) Glucose reverses fasting-mediated induction of PGC-1α and ALAS-1. Wild-type and liver-specific PGC-1α knockout animals were fasted
for 6 hr and subsequently injected with vehicle, glucose, or glucose and insulin. After 30, 60, or 120 min, respectively, mice were sacrificed,
livers were harvested, and relative PGC-1α and ALAS-1 expression levels were determined.
(F) Phenobarbital induces ALAS-1 independent of PGC-1α. Wild-type and liver-specific PGC-1α knockout animals were injected i.p. with
vehicle (saline) or phenobarbital (100 mg/kg). Sixteen hours after injection, livers were harvested, and relative mRNA levels of PGC-1α, ALAS-1,
and cytochrome P450 2b10 and 3a11 (Cyp2b10 and Cyp3a11, respectively) were determined by semiquantitative PCR. Data in (A) and (C)–
(F) are represented as mean ± standard deviation. *p < 0.05 between wild-type and knockout animals in Student’s t test.ficial effect of glucose in acute porphyric attacks is me-
diated by the glucose-triggered increase of plasma in-
sulin. ALAS-1 mRNA is not regulated by fasting in the
knockout mice, and, thus, no effect of glucose and/or
insulin on ALAS-1 transcript levels could be observed.
Taken together, these data strongly suggest that
PGC-1α may be involved in fasting-induced acute
porphyric attacks. Apart from fasting, certain drugs
s
t
d
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t
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h
ttrongly regulate ALAS-1 levels and, therefore, are able
o precipitate porphyric attacks (Elder et al., 1997; Tha-
ani et al., 2000). There are two different classes of
hemicals that perturb heme homeostasis: first, drugs
hat increase heme biosynthesis by inducing ALAS-1,
nd second, compounds that block different steps of
eme biosynthesis and thus generate various heme in-
ermediates. Representative for the first class of drugs,
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48Figure 6. Ectopic Expression of PGC-1α Elicits an Acute Porphyric Attack
(A) Lead (Pb) and 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) inhibit heme biosynthesis at different steps.
(B and C) Ectopic PGC-1α expression increases ALAS-1 levels and heme intermediates. Adenoviral GFP or PGC-1α was injected into the tail
veins of wild-type animals, which were fasted 4 days later and treated with corn oil and DDC (10 mg/kg) for 24 hr. Transcript levels of PGC-
1α (B) and ALAS-1 (C) were determined after the mice were sacrificed 24 hr later.
(D and E) Plasma of tail-vein-injected animals was collected, and 5-aminolevulinic acid (ALA) levels (D) and porphobilinogen (PBG) levels (E)
were determined. Data in (B)–(E) are represented as mean ± standard deviation. *p < 0.05 between GFP- and PGC-1α-infected animals in
Student’s t test.we chose the barbiturate phenobarbital (PB), a classi-
cal drug that precipitates porphyric attacks in patients.
As shown in Figure 5F, no significant difference in PB
induction of ALAS-1 and the prototypical PB-target
genes cytochromes P450 Cyp2b10 and Cyp3a11, two
microsomal cytochromes P450 with a heme moiety as
prosthetic group, was observed between wild-type and
liver-specific PGC-1α knockout animals. These data in-
dicate that the role of PGC-1α in ALAS-1 regulation
does not extend universally to all other mechanisms,
such as the induction by barbiturate drugs (Fraser et
al., 2002, 2003; Podvinec et al., 2004).
Elevated Expression of PGC-1 Causes Acute
Attacks in Chemical Porphyria
The consequence of ALAS-1 regulation by PGC-1α in
fasting and feeding for acute porphyric attacks wassubsequently tested using proporphyrogenic drugs
that are known to function by disruption of the pathway
of hepatic heme biosynthesis. Two members of this class
of chemicals are lead (Pb) and 3,5-diethoxycarbonyl-
1,4-dihydrocollidine (DDC) (Figure 6A). Lead intoxica-
tion produces symptoms resembling those of acute
hepatic porphyria (May et al., 1995). Because of its abil-
ity to replace other ions such as zinc and to block
thiol groups, lead inhibits several enzymes in heme
biosynthesis, most importantly ALAD. Another drug
widely used to induce porphyria in systems that lack
the genetic predisposition for this disorder, DDC,
causes accumulation of N-methyl protoporphyrin, a po-
tent inhibitor of ferrochelatase (De Matteis et al., 1973).
In gain-of-function experiments, mice were injected i.v.
with adenoviral GFP and PGC-1α. These animals were
subsequently fasted and treated with vehicle (corn oil)
or DDC for 24 hr. DDC did not change adenoviral ex-
Cell
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49pression of PGC-1α mRNA (Figure 6B). In contrast,
ALAS-1 transcript levels were elevated 10-fold in ani-
mals that received both PGC-1α adenovirus and DDC
(Figure 6C). This high induction of ALAS-1 was re-
flected in the dramatically increased levels of the heme
precursors 5-ALA and PBG in their plasma (Figures 6D
and 6E), to 9 M and 27 M, respectively. Importantly,
these are levels that are seen in acute attacks in mouse
models of porphyria. Thus, in wild-type animals with
chemical porphyria, elevation of PGC-1α expression in
the liver results in accumulation of heme precursors
comparable to that classically observed in drug-precip-
itated acute attacks in genetic mouse models of por-
phyria (Lindberg et al., 1996, 1999).
Liver-Specific PGC-1 Knockout Animals Are
Protected from Chemical Porphyria
The requirement for PGC-1α in fasting-induced por-
phyria was tested in the liver-specific PGC-1α knockout
animals. In fasted wild-type animals treated with lead
chloride and DDC for 24 hr, increased ALAS-1 mRNA
levels were observed as compared to treatment with
their vehicles saline and corn oil, respectively (Figure
7A). In contrast, neither lead chloride nor DDC changed
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AFigure 7. Liver-Specific PGC-1α Knockout Animals Are Protected
from Chemical Porphyria
Lack of increase in ALAS-1 mRNA and heme biosynthesis interme-
diates in liver-specific PGC-1α knockout animals. Fasted wild-type
and knockout animals were i.p. injected with saline and lead chlo-
ride (PbCl2, 20 mg/kg) or corn oil and DDC (10 mg/kg) for 24 hr.
After animals were sacrificed, ALAS-1 mRNA levels (A), ALA plasma
levels (B), and PBG plasma levels (C) were determined. Data are
represented as mean ± standard deviation. *p < 0.05 between wild-
type and knockout animals in Student’s t test.
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vndogenous PGC-1α levels (data not shown). As a con-
equence of the ALAS-1 induction and the chemical
lock in the biosynthetic pathway, 5-ALA accumulates
n plasma after lead and DDC treatment (Figure 7B).
ince lead and DDC inhibit heme biosynthesis at dif-
erent steps (Figure 6A), only DDC elevates PBG levels
Figure 7C). Thus, as reported, blocking of heme bio-
ynthesis with porphyrogenic drugs results in a state of
atent porphyria in wild-type mice, comparable to the
tatus of patients between attacks, which is charac-
erized by moderately elevated levels of 5-ALA and
BG (De Matteis, 1973). In an actual acute attack,
-ALA and PBG levels rise to those observed in the
ain-of-function experiment shown in Figure 6D and
E. Strikingly, lead and DDC completely fail to induce
ither ALAS-1 mRNA (Figure 7A) or plasma 5-ALA (Fig-
re 7B) or PBG levels (Figure 7C) in the liver-specific
GC-1α knockout mouse. These data indicate that
GC-1α is absolutely required for animals treated with
orphyrogenic drugs to enter a state of latent por-
hyria.
iscussion
hile the biochemical consequences of mutations in
he heme biosynthetic pathway are well known, the mo-
ecular mechanisms underlying the nutritional regula-
ion of hepatic porphyrias have been poorly under-
tood. Specifically, questions regarding how fasting
an precipitate porphyric attacks and why glucose infu-
ions provide therapeutic benefit have remained unan-
wered. The results presented here provide a clear-cut
echanism, deduced from biochemical and genetic
vidence: the transcriptional coactivator PGC-1α is in-
uced in the liver in fasting and potently turns on ex-
ression of the ALAS-1 gene in hepatocytes and in liver
n vivo. The induction of PGC-1α in fasting has pre-
iously been shown to be a consequence of glucagon
ction and the transcription factor cAMP element bind-
ng protein (CREB), which binds directly to the PGC-1α
romoter (Herzig et al., 2001). In addition, CREB can
lso directly activate the ALAS-1 promoter (Varone et
l., 1999).
PGC-1α activates the ALAS-1 promoter by coactivat-
ng NRF-1 and FOXO1, both of which directly bind to
he ALAS-1 promoter (Figure 6). The ability of PGC-1α
o positively regulate the ALAS-1 gene and the require-
ent for PGC-1α in the fasting induction of ALAS-1 to-
ether provide a direct explanation for how fasting can
rovoke an acute attack in an individual with a mutation
n the pathway of heme biosynthesis that results in he-
atic porphyria. Indeed, adenoviral expression of PGC-
α in mice with chemical inhibition of enzymes of heme
iosynthesis results in significantly elevated porphyrin
recursor levels reminiscent of acute porphyric attacks.
n contrast, the excess production of heme intermedi-
tes by porphyrogenic drugs is lost in the liver-specific
GC-1α knockout.
The therapeutic effect of glucose on acute hepatic
orphyria is well documented (Robert et al., 1994).
oreover, it has been established that ALAS-1 tran-
cription is inhibited by the insulin pathway involving
kt (Kappas et al., 1995; Scassa et al., 2001). Our data
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50for the first time illustrate likely mechanisms by which
glucose and the subsequent elevation of insulin, which
occurs in vivo in response to glucose, can ameliorate
an acute porphyric attack. First, increased levels of in-
sulin will certainly blunt the expression of PGC-1α. Glu-
cagon is important in PGC-1α expression, and rising
blood glucose dampens glucagon secretion (Herzig et
al., 2001; Yoon et al., 2001). Second, insulin has been
shown to activate the protein kinase Akt in the liver, and
Akt in turn phosphorylates FOXO1 (Brunet et al., 1999;
Nakae et al., 2001). Phosphorylation of FOXO1 results
in disruption of its binding to PGC-1α and its export
from the nucleus (Puigserver et al., 2003), thus inhibit-
ing PGC-1α action. Increased blood glucose levels
would therefore be expected to alter the PGC-1α mod-
ulation of ALAS-1 gene expression by two related but
independent mechanisms. This hypothesis is supported
by the reduced ALAS-1 mRNA levels in fed mice that
have constitutively elevated PGC-1α levels after tail-
vein injection of adenoviral vectors (see Figure S1 in
the Supplemental Data available with this article on-
line). Thus, despite high PGC-1α levels, ALAS-1 mRNA
transcription can be reduced by insulin-triggered nuclear
exclusion of FOXO1. Moreover, like insulin, glucose has
been shown to have an inhibitory effect on ALAS-1
transcription in cell culture (Canepa et al., 1984; Giger
and Meyer, 1981). Under our experimental conditions,
glucose alone did not significantly repress basal or
PGC-1α-induced ALAS-1 mRNA levels (Figure S2).
However, insulin and glucose together were more effi-
cient than insulin in reducing ALAS-1 expression. Thus, in
addition to its effect on insulin secretion, glucose could
directly affect ALAS-1 transcription. Candidate pathways
include the AMP-activated protein kinase (AMPK), pro-
tein phosphatase 2A (PP2A), and carbohydrate-response
element binding protein (ChREBP) (Kawaguchi et al.,
2002; Yamashita et al., 2001), although an effect of this
signaling cascade on ALAS-1 remains to be shown.
Agents that elevate hepatic PGC-1α levels are there-
fore potentially dangerous for patients with hepatic
porphyrias. Accordingly, drugs and foods that induce
PGC-1α in the liver should be avoided. Unfortunately,
because of the therapeutic high carbohydrate intake,
patients with hepatic porphyrias are prone to weight
gain. Losing excess weight is very difficult for some of
these patients because of fasting-induced acute at-
tacks. Hopefully, our findings described here might lead
to the development of more specific treatments for
these patients.
Experimental Procedures
RNA Isolation and Analysis
Total RNA was isolated from liver or cultured cells using the Trizol
reagent (Invitrogen) according to the manufacturer’s protocol. For
semiquantitative real-time PCR analysis, 1 g of total RNA was
treated with RNase-free DNase and subsequently reverse tran-
scribed with random hexamer primers (Roche Applied Science).
Relative mRNA abundance normalized to 18S rRNA levels was de-
termined with the Ct method after amplification using a iCycler
iQ real-time PCR detection system (Bio-Rad) and SYBRGreen (Bio-
Rad). Data are represented as mean ± standard deviation. Signifi-
cance is defined as p < 0.05 in Student’s t test.
Animal Experiments
All animal experiments were performed according to procedures
approved by the Institutional Animal Care and Use Committee. Ani-mals were fed standard rodent chow and housed in a controlled
environment with 12 hr light and dark cycles. For fasting experi-
ments, mice were deprived of food for the indicated amount of time
before animals were sacrificed. Drugs (phenobarbital, 100 mg/kg;
PbCl2, 20 mg/kg; DDC, 10 mg/kg) were injected i.p., and livers and
blood were harvested after 16 or 24 hr. All groups consisted of at
least three to six mice. Glucose (1 g/kg) and insulin (1.0 U/kg) were
injected i.p. into mice that were fasted for 6 hr. Data are repre-
sented as mean ± standard deviation. Significance is defined as
p < 0.05 in Student’s t test.
Generation of Liver-Specific PGC-1 Knockout Animals
Generation of animals with floxed PGC-1α alleles has been de-
scribed (Lin et al., 2004). These mice were crossed with mice that
transgenically express cre recombinase under the control of the rat
albumin promoter (Jackson Laboratory, strain B6.Cg-Tg(Alb-cre)
21MGn/J) to obtain liver-specific PGC-1α knockout mice.
Adenoviral Infection
Cultured cells were infected with adenovirus as published (Yoon et
al., 2001). Twenty-four to forty-eight hours after infection, cells were
harvested. Male Wistar rats were transduced with purified adenovi-
rus via tail-vein injection as described (Yoon et al., 2001). Mice were
tail-vein injected with 0.2 OD of cesium-chloride-gradient-purified
adenovirus. Five days later, mice were sacrificed and livers and
plasma were harvested. Data are represented as mean ± standard
deviation. Significance is defined as p < 0.05 in Student’s t test.
Cell Culture (Fao, H2.35, Primary Hepatocytes), Transfection,
and Reporter-Gene Assays
Fao rat hepatoma cells were cultured in RPMI medium with 10%
fetal calf serum. H2.35 mouse SV-40-transformed hepatocyte cells
were kept in DMEM supplemented with 4% fetal calf serum and
0.2 M dexamethasone. Primary mouse hepatocytes were isolated
and cultured as described (Lin et al., 2004). Cells were transfected
using Lipofectamine 2000 (Invitrogen) according to the manufactur-
er’s protocol. For reporter-gene assays, cells were harvested 48 hr
after transfection. Luciferase levels were determined and normal-
ized to β-galactosidase expression as published (Iniguez-Lluhi et
al., 1997). For treatment with glucose (33 mM), cells were cultured
in glucose-free DMEM (Mediatech). Data are represented as mean ±
standard deviation. Significance is defined as p < 0.05 in Student’s
t test.
Cloning of Promoter Constructs and Site-Directed Mutagenesis
The rat ALAS-1 promoter (Braidotti et al., 1993) was amplified by
PCR and cloned into the pGL3 basic luciferase reporter-gene vec-
tor (Promega). Site-directed mutagenesis was performed using
overlapping primers. All constructs were verified by sequencing.
Electrophoretic Mobility Shift Assays
Electrophoretic mobility shift assays were performed as described
(Handschin et al., 2003). Briefly, wild-type and mutant ALAS-1-pro-
moter fragments were radiolabeled and used as probes together
with in vitro-transcribed/translated proteins. Protein-DNA com-
plexes were subsequently separated by polyacrylamide gel elec-
trophoresis. FOXO1 antibody was purchased from Santa Cruz Bio-
technology.
Chromatin Immunoprecipitation
Experiments were performed using the Chromatin Immunoprecipi-
tation (ChIP) Assay Kit (Upstate) following the manufacturer’s pro-
tocol. H2.35 cells were infected with adenoviral GFP and FLAG-
tagged PGC-1α for 24 hr and treated with vehicle or 10 nM insulin
for 12 hr before cells were harvested, DNA-protein complexes
crosslinked, and immunoprecipitation reactions performed using
anti-FLAG beads (Sigma). After reverse crosslinking, DNA was puri-
fied by phenol/chloroform extraction and ethanol precipitation, and
relative levels were subsequently analyzed by PCR.
Determination of ALA and PBG Plasma Levels
When animals were sacrificed, blood was harvested by cardiac
puncture. Blood plasma was purified by centrifugation in heparin
Cell
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51tubes (Becton Dickinson) and treated as described (Mendez et al.,
1999). ALA and PBG levels in the plasma were subsequently ana-
lyzed by sequential ion-exchange chromatography using columns
from the ALA/PBG by Column Test Kit (Bio-Rad) using a modified
protocol (Davis and Andelman, 1967). PBG and ALA were absorbed
on anion- and cation-exchange resins, respectively. Following elu-
tion and conversion to pyrrole in the case of ALA, Ehrlich’s reagent
was added, and PBG and ALA levels were determined colorimet-
rically. Data are represented as mean ± standard deviation. Signifi-
cance is defined as p < 0.05 in Student’s t test.
Supplemental Data
Supplemental Data include two figures and can be found with this
article online at http://www.cell.com/cgi/content/full/122/4/505/
DC1/.
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Figure S1. Feeding Reduces ALAS-1 Levels Despite Constitutively High PGC-1α Expression 
 
Adenoviral vectors for GFP and PGC-1α were tail-vein injected into animals. After four days later, mice 
were fasted overnight and hepatic PGC-1α and ALAS-1 expression compared to fed control animals. 
Despite constant adenoviral production of PGC-1α, ALAS-1 is significantly lower in the fed vs. the 
fasted state. Data are represented as mean +/- standard deviation. n.s., non-significant; *p<0.05 between 
fasted and fed samples in Student’s t-test. 
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Figure S2. Distinct Effects of Glucose and Insulin on H2.35 Mouse Hepatoma Cells 
 
H2.35 cells were infected with adenoviral GFP and PGC-1α and cultured in glucose-free medium for 24 
hours. Cells were subsequently treated with 33 mM glucose and 10 nM insulin for 12 hours before RNA 
was isolated and relative expression of ALAS-1 determined. Although glucose alone did not significantly 
inhibit basal or PGC-1α-induced ALAS-1 levels, the combination of insulin and glucose was more potent 
than insulin by itself at repressing ALAS-1 transcription. Data are represented as mean +/- standard 
deviation. *p<0.05 between vehicle and glucose/insulin-treated cells in Student’s t-test. 
 
 
 
54
 5 Identification of Multiple HNF4α  Response 
Elements by Cross Species Sequence 
Comparison  
5.1 Comparative Genomic Analysis of ALAS1 
To identify additional putative regulatory regions of human ALAS1 a total of 66.7kb 
genomic sequence of ALAS1 was analyzed by cross-species sequence comparison. 
As illustrated in Fig.1 this region spans the entire intergenic region ranging from the 5’-
neighboring to the 3’- neighboring gene.  
At the time when the analysis was initiated, human and mouse sequences covering the 
above region were available. Annotation of rat ALAS1 gene was missing in the 
assembly, however part of the 5’-flanking region could be identified based on mouse – 
rat synteny and cross species sequence comparison. Sequences used for the analysis 
are schematically represented in Fig. 1 and were all obtained from the University of 
California Santa Cruz Genome Browser (UCSC) (http://genome.ucsc.edu).  
 
Figure 1   Overview of human ALAS1 genomic locus 
  The human ALAS1 gene is located on chromosome 3. The gene consists of 2 
uncoding and 10 coding exons and spans 16.8kb. ALAS1 is flanked by WDR51A 
(WD repeat domain 51A) and TLR9 (Toll like receptor 9) at the 5’- and 3’- end 
respectively. This intergenic region spans a total of 66.7kb which was used for the 
cross species sequence analysis. Corresponding mouse and rat sequences used for 
the multispecies alignment are indicated. Note that part of the rat sequence is 
missing in the assembly (dashed line). (from http://genome.ucsc.edu) 
First a human and mouse sequence comparison was performed using global alignment 
algorithm AVID through the VISTA portal with parameters set to at least 70% sequence 
identity over 100bp (Frazer et al., 2004a). This analysis resulted in the identification of 
a total of 30 segments of non-coding sequences, whose location with respect to ALAS1 
transcriptional start site are indicated in Fig. 2. Since global alignment algorithms miss 
rearrangement events likely to have happened during genomic evolution, we analyzed 
5  Identification of Multiple HNF4a Response Elements by Cross Species Sequence Comparison 56 
in parallel our region of interest with the local alignment algorithm now mostly used for 
aligning long genomic sequences, BLASTZ (Schwartz et al., 2003). This algorithm is 
the basis for the multispecies sequence alignments, called MULTIZ, which can be 
accessed through the UCSC genome browser. Therefore 3 species (human, mouse 
and rat) sequence alignments performed by MULTIZ were retrieved from the UCSC 
browser. (http://genome.ucsc.edu). Blocks of conserved non-coding sequences 
reported by MULTIZ were again plotted along the genomic locus of ALAS1 (Fig. 2).  
First, the results of the two alignments plotted in Fig.2 illustrates that blocks of 
conserved non-genic sequences are found along the entire genomic locus of ALAS1, 
within the 5’-flanking region, in the introns and in the 3’-flanking region. Secondly, all 
the regions reported by VISTA within the parameters used were present in the MULTIZ 
alignment, but not vive versa. Of note, the blocks of conserved non-genic regions 
reported by MULTIZ are longer, which reflects the fact that the BLASTZ algorithm is 
less stringent in allowing high scoring sequence matches to be extended to both sites. 
According to the location of conserved blocks of non-genic sequences reported by both 
algorithms we defined a total of 16 Conserved Non-Genic fragments (named CNGs), 
which were PCR amplified and cloned into a reporter vector for subsequent testing in 
cell-based transactivation assays. The location of the constructs with respect to human 
ALAS1 genomic locus and their naming, which will be used in the work below, is 
illustrated in Fig. 2.  
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Figure 2  Multispecies sequence comparison of human ALAS1 
Overview of conserved non-coding sequences in human ALAS1 gene. Transcriptional start site (TSS) is set to 0. Location of exons are 
depicted in red. Results of human - mouse comparison performed by VISTA (> 70% sequence identity over at least 100bps) are shown in 
pink. Conserved non-coding blocks of multispecies alignment (human, mouse, rat) as reported by ‘MULTIZ’ are shown in light blue. 
Accordingly, Conserved Non Genic Sequences (CNGs) were PCR amplified for subsequent testing in cell based transactivation assays (dark 
blue).  
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5.2 Multiple CNGs respond to PGC1α  - HNF4α activation 
In order to see if the CNGs contained any regulatory sequences, we first screened the 
CNG constructs in CV1 transactivation assays for a response to the versatile 
coactivator PGC-1α that is known to co-activate a large number of transcription factors 
from inside and outside the nuclear hormone receptor family. Therefore CV1 cells were 
co-transfected with empty tk luc vector, a 1.3kb long promoter fragment or the various 
CNGs in the presence or absence of PGC-1α. As illustrated in Fig. 3 a majority of the 
CNGs, namely CNG1, 3, 4, 6, 7, 9, intron10 and 3 prim showed a significant increase in 
reporter gene activity in response to PGC-1α as compared to the empty vector.  
 
Figure 3   Transactivation Screen of CNGs with PGC1α 
  CV1 cells were co-transfected with either empty tk-luc vector, a 1.3kb long promoter 
construct or the various CNG constructs along with PGC1α to screen for potential 
regulatory sequence. Co-transfection of PGC1α significantly increased the reporter 
activity of multiple CNGs including the 1.3kb promoter. Data presented result from at 
least 2 independent transfections performed in duplicates. # indicates p < 0.05 
PGC1α vs vector control. 
The data suggest that the above mentioned constructs contained response sequences 
for transactivators, which are present in CV1 cells and which are stimulated by PGC-1α 
in  a ligand independent manner. We therefore conclude that ALAS1 gene contains a 
multitude of enhancer modules spread over the entire genomic locus.  
One of the nuclear hormone receptors potently activated by PGC-1α is HNF4α. This 
liver enriched transcription factor is an important regulator of hepatic gene expression 
and has been shown to be essential for the full response of different cytochromes 
P450s to xenobiotics (Chen et al., 2005, Ferguson et al., 2005, Tirona et al., 2003). We 
hypothesized that this factor also played a role in ALAS1 regulation and hence was 
supposed to be responsible for the PGC-1α response seen in various CNGs.  
Therefore a subset of the above PGC-1α responsive CNGs were co-transfected into 
CV1 cells together with HNF4α, PGC-1α or a combination of both. CNG number 10, 
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although no significant increase in reporter activity could be observed in response to 
PGC-1α, was included in the analysis, since this region contained high scoring DR1 
elements (see below). As illustrated in Fig. 4 co-transfection of HNF4α resulted in a 
significant increase in reporter gene activity in the absence or presence of PGC-1α in 
CNG1, 3, 6, 10, intron10 and 3prim. Indeed, reporter activity of CNG10 significantly 
increased in the presence of HNF4α. Of note the clear increase in activity in the 1.3kb 
promoter construct exerted by PGC-1α was abolished in the presence of HNF4α. As 
described in chapter 4, the ALAS1 promoter regions contains a NRF1 and FOXO1 site, 
which are efficiently co-activated by PGC-1α. We therefore conclude that co-
transfected HNF4α competes with PGC-1α binding to those sites resulting in a loss of 
stimulatory effect of PGC-1α on the promoter construct.  
 
Figure 4   Multiple CNGs respond to HNF4α activation 
  CV1 cells were co-transfected with either empty tk-luc vector, a 1.3kb long promoter 
construct or the indicated CNG constructs along with HNF4α, PGC1α or a 
combination of both. HNF4α alone or in combination with PGC1α increases reporter 
activity of CNG1, 3, 6, 10, inro10 and 3prim. Note that PGC-1α co-activation of the 
promoter is inhibited in the presence of HNF4α. Data presented results from at least 
3 independent transfections performed in duplicates. * indicates p < 0.05 HNF4a vs 
vector control. # indicates p < 0.05 HNF4α + PGC1α vs PGC 1α alone. 
CNG3 and CNG4 located at minus 21kb and minus 16kb respectively harbor the CAR 
and PXR binding sites previously identified in our laboratory (Podvinec et al., 2004) and 
CNG6 the newly characterized FXR response element IR1. Functional HNF4α bindings 
sites in close proximity of CAR and PXR binding sites have been described and shown 
to be necessary for full response to PXR and CAR specific activation. In our 
experiments, CNG3 is efficiently activated by HNF4α - PGC1α, suggesting a HN4α 
binding site in close proximity to the drug response elements. In contrast, reporter 
activity of CNG4 did not significantly increase in the presence of HNF4α. However 
since binding of HNF4α to this region could be demonstrated in chromatin 
immunoprecipitation experiments described below, we suppose that repressive 
5  Identification of Multiple HNF4a Response Elements by Cross Species Sequence Comparison 60 
sequences within the full length 1453bp CNG4 construct mask a response to HNF4α 
activation.  
In summary we conclude that HNF4α responsive sequences are present at various 
regions within the human ALAS1 genomic locus. 
5.2.1 Identification of DR1 elements  
In order to identify the exact binding  sites within the HNF4α responsive CNGs we 
either pursued a classical subcloning strategy or searched the regions with two 
different web-based algorithms, NubiScan (Podvinec et al., 2002) and Cluster Buster 
(Frith et al., 2003) designed to detect transcription factor binding sites.  
5.2.1.1 Characterization of a functional HNF4α RE within CNG1 at minus 27kb 
Classical subcloning procedure was applied to identify the exact sequences conferring 
the response to HNF4α within the CNG showing the highest response in transactivation 
assays, which was the 595bp long CNG1 located at minus 27kb from the transcriptional 
start site.  
As illustrated in Fig. 5, a 247bp subclone A retained the response to HN4α as well as 
PGC1α, whereas sublcone B and C did not show any significant increase in reporter 
gene activity. The NubiScan algorithm, which has been specifically designed to identify 
nuclear hormone receptor binding sites, identified one DR1 element within the 247bp 
construct showing high similarity to the HNF4α consensus sequence. To demonstrate 
the importance of the identified DR1 in the HNF4α response, we performed site 
directed mutagenesis of one or both halfsites. Mutation of either the first or both 
halfsites resulted in a significant loss of the response to HNF4α in the presence or 
absence of PGC1α (right panel). These data clearly demonstrate the functionality of the 
identified DR1 that is located at minus 27kb from the transcriptional start site.  
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Figure 5   Characterization of a functional DR1 element within CNG1 
  A) Subcloning of the 595bp CNG1 construct results in a 247bp fragment A retaining 
the response to HNF4α and PGC1α in CV1 transactivation assays.  
  B) NubiScan identifies one DR1 element within subclone A.  
  C) Site directed mutagenesis of one or both halfsites (as indicated in B) results in a 
significant loss of the response to HNF4α and PGC1α activation. 
5.2.1.2 In silico search for HNF4α binding sites 
We next searched the additional HNF4α responsive CNGs in their entire length for 
putative HNF4α binding sites using NubiScan algorithm. This algorithm developed by 
M. Podvinec relies on the combination of nucleotide distribution weight matrices of 
single hexamer halfsites, which reflects the binding characteristic of nuclear receptors 
and indeed results in more specific prediction of functional sites than conventional 
search tools (Podvinec et al., 2002). The highest scoring DR1 elements within each 
CNG reported by NubiScan are listed in Table 1.  
In parallel, we applied an additional web based in silico approach, Cluster Buster (Frith 
et al., 2003), which has been specifically designed to find clusters of pre-specified 
motifs in long nucleotide sequences. This approach has been already successfully 
used in identifying HNF4α bindings sites (Wiwi and Waxman, 2005).  
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We therefore scanned the entire 66.7kb genomic locus of human ALAS1 for clusters of 
HNF4α consensus sites using Cluster Buster (http://zlab.bu.edu/cluster-buster/) using 
the HNF4α binding site matrix defined by the TransFac data base. The algorithm 
reported two regions containing multiple high scoring HNF4α consensus sites located 
at minus 9kb and minus 1.5kb from the transcriptional start site respectively. 
Interestingly, both regions lie within CNGs previously identified by multi species 
sequence comparison: CNG7 and CNG10. Hence these regions contain clusters of 
putative HNF4α bindings sites and in addition show a high level of sequence identity 
across species. Together these findings strongly support a regulatory function of these 
regions.  
Table 1: Overview of the DR1 elements within different CNGs 
CNG Sequence of DR1 element  Strand 
+/- 
Identification 
method 
NubiScan 
Score 
CNG1 CAGGGCTTGTCCCAAGGTCAGGCAGGC + Subcloning, 
NubiScan  
0.795 
CNG3 ATGTGTATGCGCTGTGCCCCGTCATGC - NubiScan 0.808 
CNG4 GAGGGCCAGGACAGGGGACTCAGGGGC + NubiScan 0.837 
CNG6 AGACACTAGGCCCTAAGAACTTCCAAA - NubiScan 0.801 
CNG7 GACTCAATGGCCTTTGGTCTCACTTCC - Cluster Buster 
NubiScan 
0.861 
CNG10-1 TGCACTTGGGTCCAAGTCCAAGTGCTG + Cluster Buster 
NubiScan 
0.804 
CNG10-2 ATCATTCTGGACTTTGTCCCTCTTGTT - Cluster Buster 
NubiScan 
0.860 
CNGintro10 CCTCTCCGGAGCACTGACCTTAACAGG - NubiScan 0.724 
CNG3prim TGAGCAGAGTCCTTTGACCTCGCCTCC - NubiScan 0.914 
 
 
5.3 HNF4α binds to newly identified DR1 elements in EMSAs 
Having identified multiple novel DR1 elements in the flanking region of human ALAS1 
by a combined in silico and in vitro approach, we next assessed whether HNF4α 
protein was able to bind to the DR1 elements performing electromobility shift assays. 
The following DR1 elements were selected for the binding assay: CNG1 DR1, whose 
functionality was shown by site directed mutagenesis; the highest scoring DR1 
elements identified by both NubiScan and Cluster buster: CNG7 DR1, CNG10-1 and 
CNG10-2; and the overall highest scoring element identified by NubiScan (0.9) within 
CNG3prim.  
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Figure 6   HNF4α binds to the identified DR1 elements  
  Competition EMSAs were performed using the radiolabeled oligonucleotide dimers 
of the known HNF4α response element in the ApoCIII promoter together with cold 
oligo dimers of the identified DR1 elements. A specific protein DNA complex was 
formed at the ApoCIII element in the absence of any competing oligos (lane 2). 
Unlabeled ApoCIII element (lane 3) competitively inhibited the formation of a DNA 
protein complex. CNG1 DR1 moderately inhibited the binding, whereas the mutated 
fragment had no effect. Efficient competition was observed with the DR1 elements 
within CNG7 (lane 6), both DR1 elements within CNG10 (lanes 7 and 8), as well as 
the DR1 element within CNG3prim (lane 9). 
For competition EMSAs a known HNF4α response element from the Apolipoprotein CIII 
promoter (Barbier et al., 2005) was 32P-labeled and incubated with in vitro synthesized 
HNF4α. As illustrated in Fig. 5, a specific protein-DNA complex was formed in the 
presence of HNF4α (lane 2). The formation of this complex could be competitively 
inhibited by addition of a 100-fold excess of unlabeled oligodimers. We next wanted to 
test, if unlabeled oligodimers of our newly identified DR1 elements also were able to 
compete with the binding. In fact, 100-fold excess of wildtype CNG1 DR1 element 
moderately competed for HNF4α binding, whereas the mutated fragment showed no 
competition. Efficient competition was seen with both DR1 elements within CNG10 
(lane7,8), and to a lower degree with the DR1 elements within CNG7 and CNG3prim. 
Based on these in vitro binding assays we conclude that HNF4α is able to bind to our 
newly identified DR1 elements in human ALAS1 flanking region with low (CNG1), 
moderate (CNG7 and CNG3prim) or high affinity (CNG10-1 and CNG10-2). 
5.4 HNF4α  binds to various regions in native chromatin 
To assess whether HNF4α was indeed binding to the various responsive sequences 
within the human ALAS1 gene in a native chromatin context, we performed chromatin 
immunoprecipitation (ChIP) in cultured G2F cells using an antibody against HNF4α. 
ChIP experiments demonstrate the presence of proteins within a specified region of a 
target locus in vivo. Essentially, DNA-protein and protein-protein interactions within the 
chromatin architecture are cross-linked by formaldehyde. This is followed by lysis of the 
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cells and isolation of the nuclei. Chromatin is sheared by sonication into a discrete size 
(200 - 1000 bp), which is then subjected to precipitation using antibodies against the 
protein of interest. A critical prerequisite thus is the availability of a specific antibody. 
After extensive washing, the DNA is extracted from the immunoprecipitates and used in 
PCR for identifying the genomic region of interest. In the experiment shown in Fig. 7 an 
antibody against HNF4α and a negative control IgG was used for precipitation of 
chromatin. Precipitated and purified DNA was then amplified by quantitative RT-PCR 
using primer pairs spanning the DR1 elements listed in Table 2. The location of the 
amplified regions with respect to human ALAS1 gene is illustrated in Fig. 7. The data 
are expressed as relative enrichment of our target regions as compared to a negative 
control region located in GAPDH flanking region. As illustrated in Fig.7 an enrichment 
of DNA in the HNF4α precipitate could be observed for CNG1, CNG3, CNG4, CNG7, 
CNG10 located in the 5’-flanking region, for the CNG in intron 10 (CNGintro) as well as 
for the CNG located in the 3’-flanking region (CNG3prim). To demonstrate the ability of 
our ChIP experiment to distinguish between specific regions of the ALAS1 locus, we 
tested a region within coding exon 12 lacking any putative cis-regulatory element for 
HNF4α as a negative control. Indeed, no enrichment was seen in the HNF4α 
precipitate when part of coding exon 12 was amplified.  
These data clearly demonstrate that HNF4α is bound to at least 7 distinct regions 
within the genomic locus of human ALAS1 ranging from minus 27kb to plus 19kb from 
the transcriptional start site. 
 
Figure 7   HNF4α binds within various CNGs in native chromatin 
  Chromatin Immunoprecipitation assays were performed in cultured G2F cells using 
an antibody against HNF4α or a negative control IgG. Precipitated DNA was 
amplified by RT PCR with primers pairs spanning the regions indicated in blue. An 
enrichment of DNA in the HNF4α precipitate could be observed for the regions 
within CNG1, 3, 4, 7, 10, intron10 as well as 3prim, but not with primers spanning a 
region within coding exon 12.  
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5.5 HNF4α knock-down affects drug induction 
The identification of multiple HNF4a responsive sequences together with the finding 
that HNF4α is indeed able to bind to various regions in ALAS1 genomic locus in native 
chromatin, suggest a role of HNF4α in basal expression and or regulation of ALAS1. To 
address this question we specifically targeted HNF4α by siRNA in cultures of primary 
human hepatocytes. 
5.5.1 Transient HNF4α knock-down in primary human hepatocytes 
Since hepatoma cell lines such as HepG2 and Huh7 do not show a significant and 
reproducible response of ALAS1 to classical inducer drugs such as phenobarbital or 
rifampicin, we performed a HNF4α knock-down experiment in a system, where drug 
induction of ALAS1 is preserved; i.e. cultures of primary human hepatocytes. Therefore 
primary cells were transfected with 10nM and 25nM of a pool of four different HNF4α 
specific siRNAs using HiPerfect transfection reagent as described under supplemental 
materials and methods. As seen in Fig.8, by transfecting 10nM and 25nM HNF4α 
specific siRNA pool, HNF4α mRNA level decreased to 50% and 30% respectively as 
compared with cells transfected with non-targeting control siRNA. Basal levels of 
ALAS1 significantly decreased down to 76% as compared to siRNA control when 25nM 
of HNF4α specific siRNA pool was used. No significant change could be observed at 
the lower concentration of siRNA pool. Maximal induction of ALAS1 by classical PXR 
agonist rifampicin was slightly but significantly reduced at both concentrations of 
HNF4α specific siRNA pool when compared to the non targeting siRNA control. These 
data indeed point towards a role of HNF4α in basal as well as drug induced expression 
of ALAS1, which will be discussed in Chapter 6.3. 
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Figure 8   Transient knock-down of HNF4α in cultures of primary human hepatocytes 
  A) Transfection of cultures of primary human hepatoytes with siRNA targeting 
HNF4α dose-dependently reduces HNF4α mRNA levels.  
  B) Basal expression of ALAS1 was significantly reduced when 25nM of siRNA was 
used. Maximal induction of ALAS1 my rifampicin is slightly but significantly reduced 
at both siRNA concentrations (10nM and 25nM) tested. The experiment was 
performed in triplicates in one single donor. * p < 0.05  siHNF4α vs siC control 
5.6 Appendix: Extended multispecies sequence alignment 
In the present work, we were able to identify various regulatory regions within human 
ALAS1 based on a 3 species sequence alignment (human, mouse and rat). Clearly, 
addition of other species to the alignment will increase the power of the technique, and 
will allow to further define the exact boundaries of the conserved segments (Thomas et 
al., 2003). With the availability of the chimpanzee, dog and chicken genome in 2005, 
we were able to complement the 3 species sequence alignment with these additional 
vertebrate species. The results will be briefly discussed below. 
Comparison of chicken to mammalian species resulted in the alignment of all coding 
exons, but only in one segment of conserved non-genic sequences. Obviously the 
evolutionary distance is too far, to detect regulatory regions with the algorithms 
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available. This finding is in agreement with (Hillier et al., 2004), who report that only 
30% of known regulatory regions, which were conserved between human and rodents, 
were also found in the chicken genome.  
The identified DR1 element within CNG10 (called CNG10-2) lies within the above 
mentioned region, which is evolutionary conserved not only in mammals but also in 
birds. In fact, this 88bp long stretch of conserved regions is the only human non-coding 
segment, which could be aligned to corresponding chicken sequence, suggesting high 
functional constraint of this region (Fig 10). Deletion of this region within a natural 
promoter construct will be required to decipher the importance of the element in basal 
or induced promoter activity. Using this stretch of DNA as a bait in one hybrid assays is 
a way to identify nuclear proteins bound to the region.  
 
 
Figure 9:  5 species MULTIZ alignment containing the DR1 element within CNG10.  
  The identified DR1 response element (halfsites shown in bold) at minus 1.5kb from 
the transcriptional start site is conserved from mammals to birds. MULTIZ alignment 
from http://genome.ucsc.edu 
 
We next retrieved multispecies alignment of human, chimpanzee, mouse, rat and dog 
and compared blocks of conserved segments with the results from our initial 3 species 
alignment with the 5 species alignment as illustrated in Fig. 10. Comparison shows that 
addition of the above mentioned species to the alignment did not markedly change our 
initial results in defining conserved non-genic blocks. Due to the short evolutionary 
distance within primate species, conservation occurs independent of functional 
constraint, and therefore sequence comparison does not suit our purposes in defining 
functional elements. Segments, which initially were reported to align to mouse and rat 
sequences aligned also to dog sequence, demonstrating the higher degree of 
relationship of dogs to human. 
It has been suggested that comparison of such distantly related species as human and 
mouse was ideally for identification of regulators sites, since conservation most likely 
resulted from functional constraint. At the time of writing, sequences of additional 
species were included in the conservation track from UCSC browser. These species 
include rhesus macaque, rabbit, cow, elephant and opossum with additional ones to 
follow in the near future. 
 
Human      GCAAAGTACCTGGACAC--ACCCTGGTCACCATCATT---CTGGACTTTGTCCCTCTTGTTAATGCTCAGCTGGGAAAGG
Chimpanzee GCAAAGTACCTGGACAC--ACCCTGGTCACCATCATT---CTGGACTTTGTCCCTCTTGTTAATGCTCAGCTGGGAAAGG
Mouse      G-GAAGTACCTGGACAC--GCCTCCATCTTTATCATT---CTGGACTTCGTTCTTCTTCTTGATGCCCAGCTAGGAAAGG
Dog        GGGAAGTACCTGGACAT--ATCTTGGTCACTATCACT---CTGGACTTTAGCCCTTGTACTATTGCCCAACTGGGTACGG
Chicken    GCAGAGGAACTGAGCCCCAGCCCTATGCATCACCACTCTGCTGTGCGTTGTTCCCCTGACCCAAGTGCAGCTGGGTGAGG
           * * ** * ***  *      *     *  *  ** *   **   * *    *          *  ** ** **   **
CNG10-2-DR1 
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Figure 10  Comparison of 3 and 5 species MULTIZ alignment 
  Conserved blocks of non-coding sequences as reported by 3 species (human, mouse, rat, 2004) alignment and by 5 species (human, 
chimpanzee, mouse, rat and dog, 2005) alignment are plotted along human ALAS1 genomic locus as in Fig. 2.. Addition of chimpanzee and 
dog to the multispecies alignment does not markedly redefine blocks of conserved non-genic sequences. The absence of a conserved block 
at minus 24kb and at minus 28kb in the 3 species alignment results from missing sequence data in the assembly in 2004. Only one non-
coding segments was found to be aligned to chicken (shown in pink). Of note is that this regions contains one of the identified DR1 elements. 
For explanation, see text. 
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5.7 Supplemental Material and Methods 
5.7.1 In silico analysis of human ALAS1 genomic locus 
5.7.1.1 Cross species sequence comparison 
All genomic sequences for the alignment were retrieved from the University of 
Santacruz Genome Browser (http://genome.ucsc.edu). Human mouse pairwise 
sequence alignment was performed by AVID through the VISTA portal with parameters 
set to at least 70% sequence identity over at least 100bp 
(http://genome.lbl.gov/vista/index.shtml). Multispecies sequence alignments (human, 
mouse, rat and human, chimpanzee, mouse, rat and dog) were retrieved from the 
UCSC genome browser conservation track as described below.   
5.7.1.2 Conservation track at UCSC Genome Browser 
University of Santacruz Genome Browser contains the reference sequence and 
working drafts of a large number of genomes. Genome annotations not only include 
assembly data, sequence composition, genes and gene predictions, mRNA and 
expressed sequence tag evidence but also comparative genomics data (for a recent 
overview (Hinrichs et al., 2006)). The browser provides genome wide multispecies 
alignments. UCSC generates pairwise sequence alignment using BLASTZ, and 
subsequently produces best-in genome alignments by chaining and netting as 
described in (Kent et al., 2003). Multiple pairwise sequence alignments are then 
combined into multispecies sequence alignments by a program called MULTIZ 
(Blanchette et al., 2004).  
5.7.1.3 In silico search for transcription factor binding sites 
CNGs showing a HNF4α response in transactivation assays were scanned by 
NubiScan for putative HNF4α response elements using the provided HNF4α matrix 
(based on a collection of 18 HNF4α bindings sites from literature) and a score 
threshold of 0.6 (www.nubiscan.unibas.ch; (Podvinec et al., 2002)).  
In parallel 66.7kb genomic human ALAS1 sequence was analyzed using the web-
based program Cluster Buster (zlab.bu.edu/cluster-buster) to identify clustered DNA 
binding motifs in the entire sequence using the HNF4α binding site matrix defined by 
the TransFac data base and the default cluster finding parameters (cluster score 
treshold of 5) (Frith et al., 2003).  
5.7.2 Plasmid Construction 
Fragments of human ALAS1 flanking region were PCR amplified using the previously 
isolated PAC clone harboring ALAS1 gene as template (Podvinec et al., 2004) and 
Pwo DNA Polymerase (Roche Diagnostics, Rotkreuz, Switzerland). Primers were 
designed using Primer 3 software (primer3_www.cgi v 02) with the following 
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parameters: 24nt in length, 50% GC content, Tm 60°C, and restrictions sites added as 
indicated in Table 2. All fragments were cloned into pGL3 tk luciferase vector (Podvinec 
et al., 2004). Subfragments of the CNG1 construct were generated using standard 
cloning procedures. The mutated 247bp construct was generated by PCR using 
complementary oligonucelotides mutated in the DR1 site (see Table 2) and Pfu Turbo 
DNA Polymerase (Stratagene, La Jolla, CA, USA). The products were digested with 
DpnI (New England Biolabs) to remove the parental DNA template and selected for 
constructs containing mutations. Plasmid DNA was prepared using the Qiagen sytem. 
All constructs were verified by sequencing.  
5.7.3 CV1 transactivation assay 
Transactivation assays were carried out in CV-1 (monkey kidney) cells, which were 
maintained in high glucose (4500mg/l) Dulbecco’s Minimum Essential Medium (Gibco 
BRL, Basel, Switzerland) supplemented with 10% heat inactivated fetal bovine serum 
(Gibco BRL), 50U/ml penicillin and 50µg/ml streptomycin (Gibco BRL). Prior to 
transfection, cells were expanded for 3 days in DMEM-F12 without phenol red (Gibco 
BRL) and supplemented with 10% charcoal treated FBS. Subsequently, cells were 
plated onto 96- well dishes at a density of 25 000 cells per well and grown overnight. 
Cells were transiently transfected in OptiMemI (Invitrogen) using 1µl of LipofectAMINE 
reagent (Invitrogen) per well. Transfection mixes contained 8 ng receptor expression 
vector, 20ng coactivator expression vector, 20ng reporter vector and 60ng pRSV-βGal 
to a total of 108ng DNA per well. After 24h, medium was changed to DMEM-F12 
supplemented with 10% charcoal stripped delipidated FBS (Sigma). 24h later, cell 
extracts were prepared using 200µl of passive lysis buffer (Promega) and 10µl of the 
supernatants were assayed for luciferase activities using the luciferase assay kit 
(Promega) and a Wallac 1420 Multilabel Counter. β-galactosidase activities were 
measured as previously described (Podvinec et al., 2004). Luciferase levels were 
normalized against β-galactosidase values to compensate for variation in transfection 
efficiency. Data are presented as mean +/- standard deviation. Statistical significance is 
defined in two-tailed students t-test as p < 0.05 or p < 0.01 as indicated in the figures. 
5.7.4 G2F Human Hepatoma Cell line 
Generation of G2F cell line, a subclone of HepG2, has been described (Rencurel et al., 
2005). G2F cells were maintained in Dulbecco’s Minimum Essential Medium (Gibco 
BRL, Basel, Switzerland) supplemented with 10% heat inactivated fetal bovine serum 
(Gibco BRL), 1µM dexamethasone (Sigma, Buchs, Switzerland), 50U/ml penicillin and 
50µg/ml streptomycin (Gibco BRL). Cells were passaged every 2 to 3 days.  
5.7.5 Chromatin Immunoprecipitation 
ChIP analysis was performed using the ChIP-IT kit, according to the manufacturer's 
instructions (Active Motif, Carlsbad, CA). G2F cells were grown in 150-mm dishes to 
70-80% confluence in Dulbecco's modified Eagle's medium containing 10% fetal bovine 
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serum. After culturing the cells 24h in serum free condition, medium was changed to 
fixing medium containing 1% formaldehyde, and the cultures were incubated for 10 min 
at room temperature. The cells were washed twice with ice-cold PBS and treated with 
glycine to stop fixation. The cells were scraped in PBS containing protease inhibitors, 
collected by centrifugation, lysed in SDS-lysis buffer supplemented with protease 
inhibitors, and sonicated for 8 cycles (10-s pulse and 30-s rest on ice). The sonication 
conditions were optimized by procedures as described in the manufacturer's 
instructions and examined by agarose gel electrophoresis to determine generation of 
DNA fragments between 200 and 1000 base pairs in length. Sheared chromatin was 
immunocleared with protein G-agarose slurry for 1 h at 4 °C. A portion of the 
precleared chromatin was stored and labeled as "input DNA." The remaining chromatin 
was immunoprecipitated with rabbit polyclonal HNF4 antibody (sc-8987) and normal 
rabbit IgG supplied with the ChIP-IT kit as a negative control. After overnight 
incubation, the immunoprecipitates were washed sequentially with wash buffers for 2 
min each. Protein-DNA complexes were eluted from the antibody with freshly prepared 
elution buffer (1% SDS, 0.1 M NaHCO3). Formaldehyde cross-links were reversed by 
addition of 200 mM NaCl and heating at 65 °C for 4 h in the presence of RNase A. DNA 
was purified using proteinase K treatment and purification columns provided by the kit. 
RT-PCR was performed using 1:10-diluted input DNA and 3 µl of immunoprecipitated 
DNA from a 100-µl DNA extraction with the optimized primer pairs as indicated in Table 
2. 
5.7.6 Transfection of Primary Human Hepatocytes with siRNA 
Primary human hepatocytes were plated at a density of 15000 cells/ well into collagen 
coated 24-well plates in DMEM supplemented with 10%FBS, 1µM dexamethasone and 
penicillin/streptomycin. Cells were transfected with 10 and 25nM siRNA against HNF4α 
(SMARTpool Dharmacon) and corresponding amount of siControl (Qiagen, non-
silencing control, Alexa 488 Fluor labeled) using HiPerfect (Qiagen) according to the 
manufacturers fast-forward protocol. Briefly, siRNA was diluted in 100µl DMEM (w/o 
additives) per well to a final concentration of 10 or 25nM and subsequently 3µl of 
HiPerfect transfection reagent per well was added to the diluted siRNA. After a 5-10min 
incubation at R/T, the siRNA/HiPerfect mixture was then added dropwise to the cells. 
After overnight incubation of the cells in FBS containing DMEM, medium was replaced 
by serum free Williams E supplemented with 0.5x ITS, hydrocortisone (Sigma) and 
50U/ml penicillin and 50µg/ml streptomycin (Gibco BRL). Cells were induced 38h after 
transfection and plating and harvested 10h later. RNA was isolated and relative 
expression levels of ALAS1 were determined as described in chapter 3. 
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Table 2: Primers used for cloning, mutagenesis, EMSAs and ChIP RT-PCR 
Name Sequence (from 5’ to 3’) Purpose 
CNG 1 -fw ggGGTACCAGCCCCATCAATGCTATCAG Cloning 
CNG 1 -rv ccgCTCGAGTAAAGCAGGGAAAGGGAAGG Cloning 
CNG2 -fw atgGCTAGCCTATTGCACTAGGCCCACCT Cloning 
CNG2 -rv ccgCTCGAGGGTTTGGCTACTTTGGGACA Cloning 
CNG3 –fw cgGGTACCCAGCTGAGGATCCCTGTTGT Cloning 
CNG3 –rv ccgCTCGAGCCTACCCCCACCACTCTTTT Cloning 
CNG4 –fw cgGGTACCACCACAGGCCTAGAACATGG Cloning 
CNG4 –rv ccgCTCGAGCTGCTGTTGGACCACACTTG Cloning 
CNG5 –fw atgGCTAGCCAAGCTCTGGAAGGACTTGG Cloning 
CNG5 –rv ccgCTCGAGTGGTGTAGCTGGTGGGAAG Cloning 
CNG6 –fw cgGGTACCGGTGGAGAATCTGAGGTCCA Cloning 
CNG6 –rv ccgCTCGAGCTCTTCCTTGACCACCACCT Cloning 
CNG7 –fw cgGGTACCGAAAAGGCTTCCCCAAGATA Cloning 
CNG7 –rv ccgCTCGAGGGAGCTGGAGTCAGGATGTA Cloning 
CNG8 –fw cgGGTACCGATTGAGACCCTCCTGGCTA Cloning 
CNG8 –rv ccgCTCGAGGGGTGTCAGTGCCCTTCTAT Cloning 
CNG9 –fw atgGCTAGCAAAAGTCCCCAGCGTCATC Cloning 
CNG9 –rv ccgCTCGAGGCCAAAGCAGAAAGAACTGG Cloning 
CNG10-fw agtGGTACCTGTTTCCCAATCTTTCTCTA Cloning 
CNG10-rv atgGCTAGCCTCAGCTGTGGCACTTTCTG Cloning 
CNGintro1 –fw cgGGTACCAGAGTCTTCCCTGCCTGGAT Cloning 
CNGintro1 –rv ccgCTCGAGCGGGTCACCAACTTCTTCAT Cloning 
CNGintro2 –fw cgGGTACCGGGTGTGGGCTTGTAAGAAA Cloning 
CNGintro2 –rv ccgCTCGAGACAAAGAGGCTTGCTGTTGC Cloning 
CNGintro3 –fw cgGGTACCGGCCCTCAGATTTGTGTATG Cloning 
CNGintro3 –rv ccgCTCGAGGGGGAGCCTTGAGTTCTCTG Cloning 
CNGintro10 –fw cgGGTACCAATGGCCTGTCTCTGATTGG Cloning 
CNGintro10 –rv ccgCTCGAGGCCTCTGAAGGGCTTCAATTA Cloning 
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Name Sequence (from 5’ to 3’) Purpose 
CNG3prim –fw cgGGTACCCCACCCACAATGACTTTTCC Cloning 
CNG3prim –rv ccgCTCGAGCTTTGGCCTCCCAGAGTGTT Cloning 
C1 mt1  AGCTCAGGGCTTGTCCCATCTAGAGGCAGGCCTGCGGATGAG Mutagenesis 
C1 mt2 GCAGGGCAGCTCAGGGCTAAGCTTATCTAGAGGCAGGCCTGC Mutagenesis 
ApoCIII-DR1 CAGCAGGTGACCTTTGCCCAGCGCCC EMSA 
C1-DR1-wt CAGGGCTTGTCCCAAGGTCAGGCAGGC EMSA 
C1 DR1-mt  CAGGGCTTGTCCCATCTAGAGGCAGGC EMSA 
C6-IR1 TGTGACAAGGTCACAGCCCCCGAGGCA EMSA 
C6-IR1-mt TGTGACATCTAGACAGCCCCCGAGGCA EMSA 
C7-DR1 GACTCAATGGCCTTTGGTCTCACTTCC EMSA 
C10-1-DR1 TGCACTTGGGTCCAAGTCCAAGTGCTG EMSA 
C10-2-DR1 ATCATTCTGGACTTTGTCCCTCTTGTT EMSA 
CNG3p-DR1 TGAGCAGAGTCCTTTGACCTCGCCTCC EMSA 
ChIP-CNG1-fw GCTATCAGTTTCCCCTGCCTAC ChIP  
ChIP-CNG1-rv GACACTAATGAAGAGCTCATGGAA ChIP  
ChIP-CNG3-fw ACCGTGTGTCCATGTTTATGTGT? ChIP  
ChIP-CNG3-rv ACACTTTGACTCTTGGCCTCTACT? ChIP  
ChIP-CNG4-fw ACAGGCCTAAGCTAAACCTTTCC? ChIP  
ChIP-CNG4-rv GAGCACTCTGTGTTCTTGATGC? ChIP  
ChIP-CNG7-fw ATGACAATTCTAAGGCAGGTGAAT? ChIP  
ChIP-CNG7-rv ATCCACCTCCTTGTCAAGACC? ChIP  
ChIP-CNG10-fw AAATGCAAAGTACCTGGACACAC? ChIP  
ChIP-CNG10-rv AACACATAAAGTGTAGGGCTTGG? ChIP  
ChIP-intro10-fw CTGACTTCACCAAGAGAAGAAAGC ChIP  
ChIP-intro10-rv CAACTGTGACATCAACAGTGCTAC? ChIP  
ChIP-3prim-fw AGACTGAGACAGCTGAAGCAAAAC? ChIP  
ChIP-3prim-rv CCTGCCTAGGTGTATGGTTTTATC? ChIP  
ChIP-ex12-fw GAGAATCTGCTAGTCACATGGAAG? ChIP  
ChIP-ex12-rv GTAGCCAATAGCAGAAAGAACCAC? ChIP  
 6 Overall Discussion 
6.1 Bile acids positively regulate human ALAS1 
In the present work (Chapter 3) we identified and characterized human ALAS1 as a 
novel direct target of bile acid activated nuclear receptor FXR. Both natural and 
synthetic agonist of FXR increase ALAS1 mRNA as well as activity in cultures of 
primary human hepatocytes. The most abundant primary bile acid in human bile, 
chenodeoxycholic acid (CDCA), was able to increase ALAS1 mRNA at near 
physiological concentration in human liver slices, a system where the architecture of 
human liver still is intact. In agreement with this we identified and characterized a FXR 
response element in the 5’-flanking region of human ALAS1, which triggers the 
response to CDCA in reporter gene assays and is able to bind FXR/RXR heterodimer 
in gel shift assays.  
The activation of ALAS1 by bile acids can be fitted in the physiological context of bile 
acid metabolism. Bile acids are the major product of cholesterol metabolism. In addition 
to their physiological role in dietary fat absorption new biological functions of bile acids 
as signaling molecules have been discovered, in particular in lipid and glucose 
homeostasis (Claudel et al., 2005). Since accumulation of bile acids causes liver cell 
damage and eventually cirrhosis, their level needs to be tightly controlled. One major 
governor of this process is FXR, representing the physiological bile acid sensor (Wang 
et al., 1999). FXR not only represses de novo bile acid synthesis but also switches on a 
detoxification machinery consisting of metabolizing enzymes and biliary efflux transport 
proteins. The enzymes induced by FXR include UDP-glucuronosyltransferases (Barbier 
et al., 2003), sulfotransferases (Song et al., 2001), or the transport proteins, such as 
MRP2 (Kast et al., 2002) as well as cytochrome P450 CYP3A4 (Gnerre et al., 2004). 
Since a functional heme protein such as CYP3A4 requires heme as a prosthetic group, 
a coordinated supply with heme is required. Our results presented in Chapter 3 provide 
a model how apocytochrome and heme synthesis is activated via the coordinate action 
of FXR on CYP3A4 and ALAS1, the rate limiting enzyme of heme synthesis.  
In addition to FXR, the xenosensing nuclear receptors CAR and PXR, have been 
shown to protect the liver from bile acid induced toxicity (Stedman et al., 2005). The 
three nuclear receptors all share a common set of target genes involved in 
detoxification processes (see above). PXR is activated by high concentrations of bile 
acids and by toxic secondary bile acids, whereas CAR does not seem to be directly 
activated bile acids (Staudinger et al., 2001). Studies in mice lacking the two 
xensoensing receptors however have demonstrated that both receptors are required for 
an efficient removal of bile acids from the body (Stedman et al., 2005). Again, in 
response to toxic levels of bile acids ALAS1 is directly targeted by CAR and PXR to 
ensure adequate supply of heme for bile acid hydroxylating CYP3A4 (Podvinec et al., 
2004, Fraser et al., 2003). Together, these findings demonstrate that ALAS1 is a crucial 
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accessory enzyme for detoxification of endogenous as well as exogenous compounds. 
Direct targeting of ALAS1 by CAR, PXR as well as FXR is in agreement with the model 
of a multifactorial and redundant detoxification system the liver has evolved to adapt to 
potentially toxic compounds (Eloranta and Kullak-Ublick, 2005). 
Interestingly, our findings that bile acids increase ALAS1 in human liver goes in line 
with a well known, although only incompletely understood clinical observation: 
Increased urinary porphyrin excretion in humans is commonly seen in hepatobiliary 
diseases accompanied by cholestasis (Rocchi et al., 2005, Doss M, 1972) (Gibson et 
al., 2000). Of course, impaired bile flux in cholestatic conditions affects biliary excretion 
of lipohilic porpyhrins, such as coproporhyins. An increased active synthesis of 
porphyrins in response to cholestatic conditions has already been suggested by several 
authors (Rocchi et al., 2005, Doss M, 1972). The molecular mechanism has not been 
studied so far. The present work now identifies CDCA as a potent inducer of ALAS1 in 
cultures of primary human hepatocytes as well as in human liver slices. Since the main 
bile acid retained in cholestasis in human is CDCA, direct activation of ALAS1 and 
subsequently heme synthesis by increased CDCA levels may contribute to the above 
mentioned clinical phenomenon. A detailed analysis of porphyrins and their precursors 
in the urine of cholestatic patients could test this hypothesis. 
Our functional data clearly demonstrate that hepatic ALAS1 is differently regulated in 
humans and in mice. Treatment of mice with synthetic FXR agonist GW4064 as well as 
feeding a diet rich in cholic acid results in a repression of hepatic ALAS1 mRNA. The 
mechanism underlying this species specific effect remains purely speculative so far. 
Interestingly, the repression of murine ALAS1 was absent in FXR -/- mice (data not 
shown). We therefore hypothesize, that a FXR SHP dependent pathway might be 
responsible for the repression of ALAS1 by bile acids in mice. SHP has been shown to 
repress a variety of transcription factors from inside (Bae et al., 2004) and outside 
(Yamagata et al., 2004) the family of nuclear hormone receptors. Putative targets of 
SHP repression on murine ALAS1 include the CAR response element located at minus 
16kb (Fraser et al., 2003) or the newly characterized FOXO1 site in the promoter 
(Chapter 4). Further studies, such as overexpression of SHP in mouse hepatocytes, 
should provide insight into this pathway. Of note, in agreement with our functional data, 
the IR1 element in human ALAS1 flanking region is not conserved in rodents, but rather 
seems to be primate invention. Major differences between human and rodents in 
cholesterol and bile acids homeostasis are a well-established feature; i.e mice cope 
with excess cholesterol in the diet by stimulation of its conversion into bile acids via a 
liver X receptor (LXR) dependent mechanism, which is not present in humans 
(Goodwin et al., 2003b).  
Human specific targets of FXR have been previously described and include hepatic 
lipase (Sirvent et al., 2004), α-crystallin (Lee et al., 2005) and peroxisome proliferative 
receptor α (Pineda Torra et al., 2003). There is a rapidly growing number of pathways 
regulated by bile acids, dependent and independent from FXR (for a recent review: 
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(Claudel et al., 2005) (Houten et al., 2006), and the list is far from being complete. 
Future progress in this field should shed light into the species-specific response 
reported herein. 
Bile acids, apart from activating FXR and all its target genes in liver, serve also as 
signaling molecules with endocrine functions (Houten et al., 2006). Circulating bile 
acids, acting via a FXR independent pathway, were recently shown to robustly increase 
PGC-1α expression and mitchondrial activity and oxidative phosphorylation in 
peripheral tissue (Watanabe et al., 2006). ALAS1 is a well established marker of 
mitochondrial activity in skeletal muscle, and coregulated with genes involved in 
oxidative phosphorylation via the action of PGC-1α ((Patti et al., 2003) and Chapter 4). 
These findings suggest that ALAS1 may well be target of bile acid signaling in 
extrahepatic tissues. Moreover we hypothesize that such an FXR independent 
activation of ALAS1 in extrahepatic tissue is also present in rodents.  
With the identification of ALAS1 as a direct target of bile acid signaling in human liver, 
we add another link between bile acid signaling and mitochondrial function. 
Our findings may have clinical implications in cases of hypersensitivity of ALAS1 to 
external stimuli, such as it is the case in acute hepatic porphyrias. Due to a relative 
heme deficiency, the strong negative feedback exerted by heme controlling ALAS1 is 
reduced, and porphyrin synthesis is excessively stimulated without control whenever 
ALAS1 is activated. Known triggering factors include drugs, alcohol, fasting, sex 
steroids and all forms of stress, however most of the triggering events remain obscure 
(von und zu Fraunberg et al., 2005). It has long been assumed, that ALAS1 was 
indirectly upregulated via a diminishing regulatory heme pool upon heme consuming 
stimuli. Previous work in our laboratory however revealed that drugs directly upregulate 
ALAS1 at the transcriptional level via the xenosensing nuclear hormone receptors CAR 
and PXR (Podvinec et al., 2004, Fraser et al., 2003). We now propose a similar 
inducing effect on ALAS1 mediated via bile acid activated FXR. Hence our data imply 
that elevated levels of bile acids, such as in cholestatic conditions, may have the 
potential to trigger acute attacks or worsen the course of the disease in porphyric 
patients. Due to the limited number of patients, we are not aware of such a 
phenomenon neither in practice nor in literature. However, disturbed bile acid 
homeostasis may well account for the high number of attacks, whose triggering events 
are unexplained. Therefore analysis of bile acids in the serum of patients suffering from 
an acute attack is required, in order to test this hypothesis.  
6.2 Nutritional Regulation of ALAS1  
The clinical characteristics of acute hepatic porpyhrias since long have suggested that 
hepatic heme synthesis is controlled by the nutritional status. Caloric restriction, such 
as fasting, is one of the well established factors, which may trigger acute 
neuropsychiatric attacks in susceptible patients. On the other hand, high carbohydrate 
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load administrated as glucose infusion at the onset of an attack was beneficial to some 
individuals (Thunell et al., 2000). However the molecular basis of these counteracting 
effects has remained obscure. We now demonstrate that both responses are under the 
control of PPARγ coactivator alpha, PGC-1α. 
PGC-1α regulates mitochondrial biogenesis and oxidative metabolism. Its expression in 
liver is low in the fed state, but it strongly increases upon fasting and subsequently 
turns on the entire fasting response of the liver, including glucoenogenesis, 
ketogenesis and fatty acid oxidation (Lin et al., 2005a). Our data demonstrate that 
hepatic heme synthesis is also targeted by PGC-1α via direct transcriptional 
upregulation of ALAS1. Fasting experiments in mice showed that ALAS1 transcripts are 
increased in a similar manner than to gluconeogenic enzymes, phosphoenolpyruvate 
carboxykinase PEPCK and glucose 6-phosphatase, which are under control of PGC-
1α. Overexpression of PGC-1α in mouse hepatocytes and in liver in vivo resulted in a 
robust induction of ALAS1 expression levels, suggesting a direct effect of this 
coactivator on ALAS1. In agreement with this, we found that PGC-1α activates ALAS1 
via coactivation of nuclear respiratory factor 1 (NRF1) and forkhead transcription factor 
FOXO1, both of which directly bind to ALAS1 promoter. The formation of a PGC-1α 
complex at both distinct sites in the promoter could also be verified in a native 
chromatin context. Importantly, the fasting response of ALAS1 was blunted in liver 
specific PGC-1α knock-out animals. Taken together these data allow to set-up a likely 
mechanism how fasting can trigger an acute attack in susceptible patients. Indeed, in 
an animal model of acute hepatic porphyria, induced by the administration of inhibitors 
of heme synthesis, fasting and concomitant overexpression of PGC-1α leads to the 
accumulation of porphyrin precursors in the blood of the mice, reflecting the 
biochemical characteristics of an acute attack in humans. Demonstrating the specificity 
of the PGC-1α effect, the excess accumulation of porphyrin precursors was absent in 
fasted liver specific PGC-1α knock-out animals. In conclusion, these findings point 
towards a master regulatory role of PGC-1α in the fasting response of ALAS1.  
How can then the beneficial effect of high carbohydrate load on porphyric symptoms be 
explained? As a matter of fact insulin levels in vivo rise upon nutrition. A repressive 
effect of insulin on ALAS1 expression has been already described in hepatoma cell 
lines (Scassa et al., 2001). Our data now provide a mechanistic explanation for this 
phenomenon. We show that the strong stimulatory effect of PGC-1α on FOXO1 activity 
at the promoter is sensitive to insulin. It is well known that FOXO1 is a direct target of 
the insulin-signaling pathway in liver (Nakae et al., 2001). Insulin activates Akt, a key 
protein kinase downstream of the insulin receptor, which in turn phosphorylates 
FOXO1. This then leads to nuclear exclusion of this transcription factor and subsequent 
loss of activation of its target genes. As demonstrated in chromatin immunoprecipitation 
experiments, recruitment of PGC-1α to the FOXO1 site in ALAS1 promoter is abolished 
in the presence of insulin. In contrast to the wildtype protein, a mutated form, which 
cannot be phosphorylated by Akt anymore, stimulates ALAS1 promoter activity in either 
the presence or absence of insulin. These finding clearly suggest that the repressive 
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effect of insulin on ALAS1 promoter activity requires a functional FOXO1 protein. So 
far, multiple ways are known, how insulin dampens ALAS1 promoter. The insulin 
counteracting hormone glucagon has been shown to stimulate ALAS1 via an axis 
involving protein kinase A (PKA) and activation of cAMP response element binding 
protein CREB in the promoter of ALAS1 (Giono et al., 2001). The same pathway also 
controls PGC-1α expression (Herzig et al., 2001). Hence, insulin, by counteracting this 
stimulatory effect of glucagon, represses ALAS1 as well as PGC-1α expression. And, 
as described above, insulin disturbs the co-activation of FOXO1 by PGC-1α. In 
addition, it is likely that HNF3beta, whose binding sites are flanking the newly identified 
FOXO1 site in ALAS1 promoter as described by Scassa et al. (Scassa et al., 2004), 
contributes to the nutritional regulation. HNF3beta (alternatively called FOXA2) like 
FOXO1 is induced in the fasted state and its activity is repressed by insulin signaling 
through phosphorylation and nuclear exclusion (Wolfrum et al., 2004).  Altogether, this 
results in a potent repression of ALAS1 in response to high carbohydrate load.       
Like insulin, glucose has been shown to exert a inhibitory effect on ALAS1 (Giger and 
Meyer, 1981). However, the exact mechanisms of this glucose effect are not fully 
resolved. It may well involve additional pathways, as will be briefly discussed below.  
Changes in cellular energy status activate a number of signaling cascades. Among 
those is the AMP activated kinase AMPK, which serves as the major energy sensor of 
the cell (Kahn et al., 2005). Activated by any kind of cellular stress, such as hypoxia, 
osmotic stress or energy depletion, AMPK switches off all ATP consuming processes, 
while it switches on ATP producing pathways including oxidative phosphorylation. In 
muscle, it has been previously shown that AMPK targets ALAS1 via its NRF1 site in the 
promoter (Bergeron et al., 2001). Therefore we hypothesized that activation of AMPK 
during caloric restriction in liver would contribute to the fasting response mediated by 
PGC-1α. However, the increase in ALAS1 transcripts upon fasting was boosted in the 
liver of mice lacking the two catalytic isoforms of AMPK (liver specific α1/α2 knock-out 
mice; personnel communication, Benoit Viollet, Institut Cochin, Paris). This rather 
suggests an inhibitory effect of AMPK on hepatic ALAS1. Interestingly, it has been 
shown that AMPK activation during fasting dampens gluconeogenesis, in order to 
prevent excess ATP consumption. The detailed mechanism has been resolved only 
recently and involves phosphorylation and nuclear exclusion of coactivator TORC2 
(transducer of regulated CREB activity 2) and consequently reduced expression of 
CREB target genes (Koo et al., 2005). Since CREB is also involved in the regulation of 
promoter activity of ALAS1, the above described repressive effect of AMPK could also 
apply for ALAS1 and might explain the in vivo findings. In summary the effect of AMPK 
on ALAS1 remains to be unraveled.  
Our results further suggest that the master regulatory role of PGC-1α is specific to the 
nutritional regulation of ALAS1 and does not apply to all inducing effects, such as drug 
induction. Although PGC-1α potently and dose dependently co-activated CAR and PXR 
at the murine ALAS1 drug response element in transactivation assays (data not 
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shown), drug induction in liver specific PGC-1α knock out animals was not altered. This 
finding suggests that additional co-activating factors are involved in the response to 
drugs in vivo. Together our data demonstrate that different inducing effects of ALAS1, 
such as fasting and drug induction, follow independent and separate pathways.  
6.3 Role of HNF4α in the regulation of ALAS1 
In chapter 5 we describe the identification of multiple HNF4a responsive sequences in 
ALAS1 gene. The presence of HNF4α in least seven distinct locations could be 
confirmed in a native chromatin context by chromatin immunoprecipitation assays. In 
the following we will discuss the putative role HNF4α in basal expression of ALAS1 as 
well as in response to drugs.   
Such a high number of regions within human ALAS1 genomic locus binding HNF4α 
suggest a role of HNF4α in basal expression and or hepatic regulation of ALAS1. 
Indeed HNF4α is recognized as the major regulator of the hepatic phenotype (Watt et 
al., 2003). The importance of HNF4α in hepatic gene expression is highlighted by a 
recent analysis combining chromatin immunoprecipitation with promoter microarrays 
(Odom et al., 2004). The authors demonstrated that hundreds of RNA Polymerase II 
bound promoters are also bound by HNF4α in human primary hepatocytes. The 
promoter array targeted regions spanning from minus 700 base pairs upstream to 
500bp downstream of the transcriptional start site of 13000 human genes. However, 
our analysis of ALAS1 reveals that the HNF4α response element with the closest 
proximity to the transcriptional start site confirmed by chromatin immunoprecipitation is 
located at minus 1.5kb (CNG10-2), explaining, why ALAS1 gene is not included in their 
huge data set of putative HNF4α target genes.   
In cultures of primary human hepatocytes we demonstrate that ALAS1 expression is 
reduced, when HNF4α expression was downregulated to 30% by siRNA specifically 
targeting HNF4α. Moreover, lowering of HNF4α levels significantly diminished maximal 
induction of ALAS1 by the classical PXR activator rifampicin. These data indeed 
suggest a role of HNF4α in basal expression as well as in drug induction of ALAS1. 
The central role of HNF4α in drug mediated induction of cytochromes P450 is a well 
recognized feature. Conditional HNF4α knock-out in fetal hepatocytes results in 
reduced expression of PXR and its target gene CYP3a11 (Kamiya et al., 2003). In liver 
specific HNF4 knock-out mice, hepatic CAR expression is drastically reduced 
(Hayhurst et al., 2001). And, as it has been reported only recently,  mice (α7 only mice) 
lacking HNF4α1, the predominant HNF4α isoform in liver, show reduced CAR 
expression as well as complete loss of 2b10 induction by typical CAR inducer 
TCPOBOP (Briancon and Weiss, 2006). Moreover HNF4α response elements have 
been characterized in various human cytochromes P450 genes and been shown to be 
essential for maximal CAR and PXR mediated drug induction (Chen et al., 2005, 
Ferguson et al., 2005, Tirona et al., 2003). We therefore suggest that ALAS1 is 
controlled by HNF4α in a comparable manner to cytochromes P450s. How the different 
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HNF4α response elements identified so far in this study cooperate for full CAR/PXR 
type activation will be addressed in ongoing studies. Therefore chimeric constructs, 
consisting of the distal enhancer elements fused to natural ALAS1 promoter containing 
the proximal HNF4α response element at minus 1.5kb will be generated. Site directed 
mutagenesis of the proximal or distal HNF4α response element will then give insight 
into their specific contribution to the full drug response. And a more efficient transient 
knock-down of HNF4α is demanded such as by adenovrial siRNA transfer in primary 
cultures, to further decipher the contribution of HNF4α in various induction processes of 
ALAS1. 
In chapter 4, we highlight the regulatory role of PGC-1α in the fasting response of 
ALAS1. The importance of HNF4α in the induction of gluconeogenic enzymes such as 
PEPCK during fasting is also well established. Rhee et al. demonstrated that the 
fasting response on gluconeogenic enzymes was lost in HNF4α liver specific knock-out 
animals (Rhee et al., 2003). Since ALAS1 has been shown to be co-regulated with 
gluconeogenic enzymes through PGC-1α, we investigated if the fasting response of 
ALAS1 also was affected in the absence of HNF4α. A first analysis of liver samples 
from fasted liver specific HNF4α knock-out animals (Hayhurst et al., 2001) and their 
controls, which were kindly provided by Insook Kim and Frank Gonzalez, did not point 
towards a dominant role of HNF4α in the fasting response (data not shown). Although 
not significantly, it seemed that ALAS1, unlike PEPCK, was still induced upon fasting in 
HNF4α knock-out animals. As reported by Rhee et al. (Rhee et al., 2003), liver specific 
HNF4α knock-out animals show a striking increase in PGC-1α expression. Apparently 
PGC-1α compensates for the lack of HNF-4α, a phenomenon, which remains 
unexplained so far. Unlike gluconeogenic enzymes, ALAS1 is additionally controlled by 
NRF1, involved in mitochondrial biogenesis and also potently co-activated by PGC-1α. 
We propose that downstream of PGC-1α multiple and redundant pathways converge 
on ALAS1, including FOXO1, NRF1 and most probably HNF-4α. The excess of PGC-
1α, which is observed in these animals, masks a potential contribution of HNF4α in the 
fasting response, further highlighting the dominant role of PGC-1α. 
Although ALAS1 is ubiquitously expressed, its regulation in liver differs from other cells 
in the body. Liver, and to a minor degree kidney and intestine, are the only organs 
where ALAS1 transcription is highly inducible by hormonal and exogenous substances 
(Thunell, 2000). In fact, these are the organs, where HNF4α is expressed. It has been 
postulated that HNF4α functions as major regulator of chromatin remodeling in early 
development (Li et al., 2000). The remodeling of the chromatin, which is largely 
transcriptional inactive, is a prerequisite for the binding of transcription factors to their 
target sequences in order to induce gene expression. Hyperacetylation of histones 3 
and 4, is one of the processes, which correlates with transcriptional activity of the 
specific region (Eberharter and Becker, 2002). In order to study the hepatocyte specific 
chromatin organization Rollini et al. transferred the entire human chromosome 14 from 
fibroblasts to hepatoma cells. Importantly, the chromatin reorganization into a 
hepatocyte specific pattern including the activation of hepatic genes failed to occur in 
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cells deficient of HNF1α and HNF4α, but could be rescued by transfection of one or the 
other factor (Rollini and Fournier, 1999). Furthermore, HNF4α, by recruiting powerful 
histone acetylases, was absolutely required to induce hyperacetylation and 
consequently the activity of the hepatocyte specific serpin locus (Baxter et al., 2005). 
Together these finding point towards a superior function of HNF4α in chromatin 
organization.   
Based on these finding, we hypothesize, that binding of HNF4α to various enhancer 
modules within the ALAS1 genomic locus, promotes hyperacetylation of those regions 
and therefore is a prerequisite for other transcriptional regulators to access their target 
sequences. Hence, HNF4α tissue expression together with its coordinative role in 
chromatin remodeling processes would determine the inducibility of ALAS1. However 
this hypothesis so far remains purely speculative. One first approach to address this 
question, would be to compare the acetylation pattern of ALAS1 genomic locus in 
hepatic (HNF4α competent) and non hepatic tissue (HNF4α deficient).   
In conclusion, our data provide first evidence that HNF4α plays a role in basal as well 
as drug induced expression of ALAS1.  
 
 
6.4 The mystery of conserved non-genic sequences of ALAS1 
In the present study we applied the in silico method of phylogenetic footprinting to 
locate novel regulatory regions of ALAS1. This approach uses cross-species 
correlation and is based on the assumption that sequence conservation also in non-
coding regions results from functional constraint. Conserved non-genic sequences thus 
most likely reflect regulatory sites (Dermitzakis et al., 2005). The method became 
possible only with the availability of whole genome sequences. Phylogenetic 
footprinting can be regarded as a filtering method, retaining conserved stretches of 
sequence of a few 100bp within a large genomic region. Using such a filter, the high 
number of false positive bindings sites reported by conventional binding site search 
algorithms can be reduced (Lenhard et al., 2003). However, there are some critical 
points to mention.  
The evolutionary distance of the species one chooses for comparison determines the 
stringency. Obviously, comparing such closely related species like human and 
chimpanzee does not only retain functional regions. On the other extreme of the 
evolutionary tree, only a few experimentally verified regulatory regions are also 
conserved in chicken. Nevertheless, alignment of human with chicken or even further 
distantly related fugu rubripes sequences has been helpful in identifying crucial 
regulatory sites fundamental for development (Boffelli et al., 2004). It hence seems 
eminent that we found one single 88bp region in the ALAS1 gene conserved between 
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human and chicken (See chapter 5) and could suggest a functional role by binding of 
HNF4α.  
The ideal candidate for comparison with the human genome has been regarded to be 
mouse, evolutionary separated by 75 million years (Nardone et al., 2004). Conservation 
of sequences between the two species may result from functional constraint as 
illustrated by Loots et al (Loots et al., 2000) . 
It was then a big surprise in the field of comparative genomics when Rubin et al 
reported, that transgenic mice, with megabase deletions of gene deserts harboring 
hundreds of human-mouse conserved non-genic regions, did not show any overt 
phenotype (Nobrega et al., 2004). Although this indicates that not all conserved gene 
deserts in mammalian genome are functional, it is not clear if it is possible to detect all 
kind of phenotypic effects. Still, these results indicate that we should be careful about 
our interpretation of selective constrain solely based on human-mouse conservation.  
Addition of further species to the alignment will certainly improve the predictive 
accuracy of phylogenetic footprinting (Thomas et al., 2003). And further improvement of 
this method can be achieved by integrating additional filtering criteria. It is now well 
established that several transcription factors act in concert in so-called enhancer 
modules, which consist of clusters of transcription factor binding sites. Therefore on 
can rather look for modules (clusters) than for single sites (Frith et al., 2003).  
At the time the present study was initiated, human, mouse and part of rat sequence 
covering ALAS1 gene were available. With the search criterion of more than 70% 
sequence identity over at least 100bp we identified a total of 30 CNGs within ALAS1. 
Accordingly a total of 16 regions, partly consisting of multiple CNGs were PCR 
amplified and tested in cell based reporter gene assays. Based on a positive response 
to the versatile coactivator PGC-1α, eight CNGs were found to contain putative 
regulatory sequences. Within the framework of the study, the specific regulatory factor 
together with its binding site could be identified as FXR within CNG6, and HNF4α within 
CNG1, CNG10 and CNG3prim.  
There is still a number of putative regulatory regions within the ALAS1 gene, whose 
function waits to be explored. Summing up the in silico and experimental evidence, our 
analysis suggests that ALAS1 is highly regulated at the transcriptional level. 
 
 7 Closing remarks and outlook 
For many years it has been assumed that acute porphyric attacks are provoked by a 
depletion of regulatory heme pool upon heme consuming stimuli and subsequent 
stimulation of heme synthesis. Previous work in our laboratory however pointed 
towards a direct transcriptional upregulation of ALAS1 by inducer drugs, which led us to 
the hypothesis that other triggering factors, such as fasting or the response to 
endogenous nuclear receptor ligands, influence ALAS1 at the transcriptional level.  
During these studies additional triggering events were identified to directly act on 
ALAS1 transcription. The versatile coactivator PGC-1α was found to be the master 
regulator of the nutritional response. PGC-1α acts via two NRF1 sites and a insulin 
sensitive FOXO1 site within ALAS1 promoter. Fasting response of ALAS1 was blunted 
in liver specific PGC-1α knock-out animals. Together, our data provide a likely 
mechanism how fasting is able to provoke an acute porphyric attack, and how a high 
carbohydrate load may alleviate the symptoms.  
Cross species sequence analysis led to the identification of numerous conserved non-
genic sequences within ALAS1 gene suggesting the presence of multiple regulatory 
regions. Subsequent screening of the CNGs to nuclear hormone receptor response in 
transactivation assays resulted in the identification of two additional nuclear receptors 
regulating ALAS1, FXR and HNF4α. Our data show that ALAS1 is targeted by bile acid 
activated nuclear receptor FXR in human, but not in mice. These findings suggest that 
elevated bile acids, such as in cholestasis, have the potential to trigger acute attacks in 
porphyric patients. Measuring serum bile acids in individuals suffering acute attacks will 
answer the questions, if elevated bile acids are causative agents in the still high 
number of attacks, whose triggering events remain obscure. 
Our studies provide first evidence that the master regulator of hepatic phenotype, 
HNF4α, is involved in basal and drug induced expression of ALAS1. The presence of 
multiple distinct regions within ALAS1 gene responding to HNF4α activation and 
binding HNF4α in vivo, led us hypothesize that HNF4α may play a superior role in 
chromatin organization of ALAS1 locus. In this model, HNF4α would provide an open 
chromatin structure for other cis-acting factors to access their binding sites as it has 
been postulated for the liver specific serpin locus (Baxter et al., 2005) (see Fig. 2). 
Tissue distribution of HNF4α would determine inducibility of ALAS1, and therefore 
explain the liver specific regulation of ALAS1.  
Different triggering events follow independent and separate pathways. PGC-1α is 
clearly required to drive the fasting response of ALAS1, but it does not seem to be 
necessary for drug induction in vivo. How nutrition and drugs differently affect ALAS1 
transcription is highlighted in the two models below.  
Studying the metabolic response of the liver to fasting and caloric restriction is a rapidly 
growing field, and the list of molecular mediators of the response is constantly 
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increasing. Indeed the complex promoter region of ALAS1 provides the basis of 
multiple mechanism to take place. The model below (Fig. 1) summarizes the known 
(solid line) and some hypothetical (dashed line) pathways, which converge on ALAS1 
promoter in response to nutritional regulation. 
 
 
 
Figure 1: Nutritional regulation of ALAS1 within its promoter 
NRF1 is critical for basal promoter activity and potently co-activated by PGC-1α (Braidotti et al., 
1993). In the fasted liver glucagon-triggered increase in cAMP levels directly stimulate ALAS1 
transcription via the cAMP-responsive element binding protein (CREB), which in parallel binds 
to the PGC-1α promoter (Yoon et al., 2001, Giono et al., 2001). The two members of the family 
of forkhead transcription factors, FOXO1 and HNF3beta, are sequestered in the cytoplasm 
under feeding conditions, however dephosphorylated in the fasted state and transported to the 
nucleus, where they also bind to ALAS1 promoter (Scassa et al., 2004, Handschin et al., 2005). 
FOXO1 activity in ALAS1 promoter is specifically enhanced by PGC-1α. In addition transducer 
of regulated CREB activity 2 (TORC2) is also known to undergo nuclear translocation in 
response to fasting where it enhances CREB dependent gene transcription (Conkright et al., 
2003). We assume that it also acts on ALAS1 promoter. Expression levels of nuclear receptors, 
CAR, PXR and HNF4α are all known to be increased in the fasted state (Maglich et al., 2004). 
They are likely to contribute to the overall fasting response. Upon feeding, increased insulin 
levels result in phosphorylation and nuclear exclusion of FOXO1 and disruption of its interaction 
with PGC-1α (Puigserver et al., 2003). Insulin also counteracts HNF3beta and TORC2 
accumulation in the nucleus. Altogether, activation of these pathways upon feeding results in a 
robust inhibition of ALAS1 transcription.  
Whereas the nutritional response of ALAS1 clearly is regulated via critical sites within 
ALAS1 proximal promoter, multiple distal enhancer regions mediate the response to 
exogenous and endogenous substances, including bile acids. Figure 2 summarizes our 
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current knowledge about the multitude of regulatory regions spread over ALAS1 
genomic locus.  
 
 
 
Figure 2: Xeno-and endobiotic response of ALAS1 via multiple distal enhancers.  
We assume that HNF4α bound to distinct regulatory regions within ALAS1 gene recruits histone 
acetyltransferases (HAT), such as CREB binding protein CBP, resulting in a open (permissive) 
chromatin structure for other cis-acting factors to access their binding sites (Baxter et al., 2005). 
CAR and PXR activated by xenobiotics induce ALAS1 transcription via the two distal enhancer 
elements located at minus 21kb and minus 16kb respectively. Bile acid activated FXR acts via 
the newly identified enhancer located at minus 14kb. Upon ligand binding, the nuclear receptors 
recruit coactivators, such as SRC1 and GRIP1, with chromatin-modifying features, resulting in 
an increase RNA polymerase II mediated transcription. PPARα and AhR ligands are also known 
to induce ALAS1 mRNA. We assume, corresponding response elements to be present within 
ALAS1 gene. Through the direct transcriptional upregulation of ALAS1, synthesis of heme for 
the incorporation into apocytochromes is guaranteed. Heme strongly represses its own 
synthesis acting on ALAS1 via multiple mechanisms, including direct transcriptional inhibition. 
Peroxisome proliferator activated receptor α PPARα; Aryl hydrocarbon receptor AhR. 
So far all events directly stimulating ALAS1 transcription are known to elicit a demand 
for newly synthesized heme. In the fasted liver, respiratory cytochromes involved in 
oxidative phosphorylation are required to restore cellular ATP levels. Ligands for the 
above described nuclear hormone receptors as well as for aryl hydrocarbon receptor 
(AhR) are known to induce hemeproteins cytochromes P450. In this context, direct 
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transcriptional upregulation of ALAS1 by endogenous, such as fasting, and 
environmental challenges, i.e. exposure to xenobiotics, provides an early and fast 
mechanism to increase heme synthesis according to the current metabolic demand for 
hemeproteins. However, as soon as cellular heme levels reach a critical level, a robust 
negative feedback of heme acting on ALAS1 comes into play, including a reduction in 
ALAS1 mRNA stability (Roberts et al., 2005) and direct inhibition of ALAS1 
transcription. The presence of a heme repressive sequence in chicken ALAS1 
promoter has been postulated (Kolluri et al., 2005). In addition heme regulates its own 
catabolism via stimulation of heme oxygenase 1. Together these mechanisms ensure a 
fine tuning of cellular hepatic heme levels according to the current metabolic need. 
 
There is still a number of putative regulatory regions within ALAS1 gene whose function 
waits to be explored. This finding appears in different light within the recently 
discovered central role of heme synthesis pathway in the maintenance of circadian 
oscillation in liver (Kaasik and Lee, 2004). During the last years it has become clear 
that peripheral organs, such as liver or kidney, are able to self sustain circadian gene 
expression (Schibler and Naef, 2005). This is achieved through a system of multiple 
feedback loops, consisting of positively and negatively acting transcription factors. 
Among those are the heme-binding PAS domain proteins, NPAS2 and Per2, whose 
transcriptional activity is enhanced by heme and repressed by carbon monoxide, the 
degradation product of heme. In addition, ALAS1 transcripts in liver oscillate highly in a 
circadian pattern. NPAS2 is required to maintain this circadian expression of hepatic 
ALAS1 and was found to activate a 5kb murine ALAS1 promoter construct (Kaasik and 
Lee, 2004). Together these findings suggest that the peripheral oscillation is not only 
dependent on a cycle of heme anabolism and catabolism but itself influences heme 
synthesis via transcriptional regulation of ALAS1.  
Moreover, triple knock-out mice with targeted disruption of the three proline- and acid-
rich (PAR) basic leucine zipper (bZip) transcription factors - albumin-D-site-binding 
protein (DBP), hepatic leukaemia factor (HLF) and thyrotroph embryonic factor (TEF) - 
which are output regulators of the peripheral clock, show reduced transcript levels of 
hepatic ALAS1 (Gachon et al., 2004). These data further demonstrate that ALAS1 is 
under the control of peripheral oscillators, implicating that various cis-regulatory 
elements for these transcription factors are present within ALAS1 gene.  
For the diverse regulatory pathways, multiple regulatory regions within ALAS1 gene are 
likely to coexist. The multitude of conserved non-genic sequences we located and were 
able to experimentally support may well reflect the complex transcriptional regulation of 
ALAS1. Insight into the transcriptional regulation of ALAS1 will finally provide novel 
pharmacological approaches to alleviate symptoms of patients suffering from acute 
porphyric attacks.  
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